<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Cell Int</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Cell Int</journal-id><journal-title-group><journal-title>Cancer Cell International</journal-title></journal-title-group><issn pub-type="epub">1475-2867</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30962764</article-id><article-id pub-id-type="pmc">6434630</article-id><article-id pub-id-type="publisher-id">785</article-id><article-id pub-id-type="doi">10.1186/s12935-019-0785-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Primary Research</subject></subj-group></article-categories><title-group><article-title>Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Peng</surname><given-names>Hao</given-names></name><address><phone>+86-0394-8208146</phone><email>penghao2018@2980.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Xiaogang</given-names></name><address><email>luoxiaogang84@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Urological Surgery, Zhoukou Central Hospital of Henan Province, No. 26 Renmin East Road, Chuanhui District, Zhoukou, 466000 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1755 6355</institution-id><institution-id institution-id-type="GRID">grid.255169.c</institution-id><institution>State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Materials Science and Engineering, </institution><institution>Donghua University, </institution></institution-wrap>Shanghai, 201620 China </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>19</volume><elocation-id>70</elocation-id><history><date date-type="received"><day>19</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Pretreatment inflammatory factors, including neutrophil, lymphocyte, platelet and monocyte counts as well as the ratios between them such as neutrophil&#x02013;lymphocyte ratio (NLR), platelet&#x02013;lymphocyte ratio (PLR) and lymphocyte&#x02013;monocyte ratio (LMR) have been suggested as potential prognostic predictors for patients with prostate cancer (PCa). However, the prognostic effects remain controversial. Therefore, the goal of this study was evaluate the prognostic values of these markers for PCa patients using a meta-analysis.</p></sec><sec><title>Methods</title><p id="Par2">Potentially relevant publications in PubMed and Cochrane Library were searched. Pooled hazard ratio (HR) with 95% confidence interval (CI) for overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), recurrence free survival (RFS) and distant metastases-free survival (DMFS) were determined using a fixed or random effects model by STATA 13.0 software.</p></sec><sec><title>Results</title><p id="Par3">Thirty-two studies involving 21,949 participants were included. Our pooled results demonstrated that a high pretreatment NLR (HR&#x02009;=&#x02009;1.55, 95% CI 1.37&#x02013;1.76), PLR (HR&#x02009;=&#x02009;1.72; 95% CI 1.36&#x02013;2.18), neutrophil (HR&#x02009;=&#x02009;1.10; 95% CI 1.03&#x02013;1.18 and monocyte counts (HR&#x02009;=&#x02009;2.25; 95% CI 1.67&#x02013;3.05) predicted inferior OS, while elevated pretreatment LMR (HR&#x02009;=&#x02009;2.27; 95% CI 1.76&#x02013;2.94) was correlated with favorable OS. Furthermore, the higher NLR (HR&#x02009;=&#x02009;1.62; 95% CI 1.29&#x02013;2.04) and monocyte counts (HR&#x02009;=&#x02009;1.75; 95% CI 1.36&#x02013;2.25), but lower LMR predicted worse PFS (HR&#x02009;=&#x02009;2.18; 95% CI 1.58&#x02013;3.02); poor RFS was only associated with NLR (HR&#x02009;=&#x02009;1.12; 95% CI 1.04&#x02013;1.20). The subgroup analysis showed that the higher NLR may be a predictive factor for OS only in patients with mCRPC and undergoing chemotherapy; while the higher PLR was only significantly associated with OS in localized PCa regardless of treatment.</p></sec><sec><title>Conclusion</title><p id="Par4">This meta-analysis reveals that pretreatment NLR, PLR, LMR, neutrophil, and monocyte counts may be effective predictive biomarkers for prognosis in patients with PCa.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Prostate cancer</kwd><kwd>Inflammatory markers</kwd><kwd>Prognosis</kwd><kwd>Meta-analysis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par26">Prostate cancer (PCa) represents a considerable health concern for the male population, with an estimated 161,360 new cases diagnosed and 26,730 death in 2017 in the United States [<xref ref-type="bibr" rid="CR1">1</xref>]. Radical prostatectomy, androgen deprivation therapy, radiotherapy and chemotherapy have been recommended for treatment of patients with PCa, however, the overall survival (OS) rate remains unsatisfactory (5-year: 77.52%; 10-year: 62.57%) due to tumor local recurrence, progression or distal metastasis [<xref ref-type="bibr" rid="CR2">2</xref>]. Therefore, how to stratify the high risk patients who will have poor prognosis because of non-response to the treatment strategies and prone to recurrence, progression or metastasis has become a hot issue urgently needed to be solved.</p><p id="Par27">Conventionally, prognosis of patients with PCa can be predicted by pathologic tumor, node, metastasis (TNM) staging, prostate-specific antigen (PSA) level [<xref ref-type="bibr" rid="CR3">3</xref>], PSA doubling time [<xref ref-type="bibr" rid="CR3">3</xref>] and Gleason score [<xref ref-type="bibr" rid="CR4">4</xref>]. Nevertheless, some clinical studies reported that patients with the same stage may have different prognoses [<xref ref-type="bibr" rid="CR5">5</xref>] and prognosis seemed to be similar among patients with different PSA levels [<xref ref-type="bibr" rid="CR6">6</xref>], indicating the insufficient accuracy of these factors for prognosis prediction. Thus, supplementary pretreatment biomarkers should be developed to assist clinicians to evaluate prognosis and further guide decision-making concerning therapeutic strategies.</p><p id="Par28">Recently, accumulating evidences suggest inflammation may play important roles in the development and progression of PCa [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Neutrophil, lymphocyte, platelet (PLT) and monocyte counts as well as the ratios between them such as neutrophil&#x02013;lymphocyte ratio (NLR), platelet&#x02013;lymphocyte ratio (PLR) and lymphocyte&#x02013;monocyte ratio (LMR) are the common, indicators for the inflammatory status in patients with cancer [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. Also, the collection of these indicators in blood is simple, noninvasive, and easily accessible. Hereby, circulating inflammatory factors may represent potential prognostic biomarkers for PCa in clinic. This hypothesis has been demonstrated by several studies: elevated NLR [<xref ref-type="bibr" rid="CR12">12</xref>], PLR [<xref ref-type="bibr" rid="CR13">13</xref>] and lower LMR [<xref ref-type="bibr" rid="CR14">14</xref>] were found to be significantly associated with worse OS. However, a handful of studies demonstrated NLR and PLR may be ineffective markers for predicting PCa prognosis [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>] or contrast conclusions were achieved (that is, higher NLR [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] may be protective factors for prognosis). These controversial conclusions may be attributed to the different study design and small sample size. Thus, it is necessary to further evaluate the prognostic significance of the above inflammatory biomarkers for patients with PCa by performing a meta-analysis that can integrate all related articles. Compared with the recently published meta-analysis that included the articles up to July 2015 [<xref ref-type="bibr" rid="CR20">20</xref>], February 2016 [<xref ref-type="bibr" rid="CR21">21</xref>] for NLR and March 2017 for PLR [<xref ref-type="bibr" rid="CR22">22</xref>], our study may collect more literatures by searching the relevant databases until August 2018, which may lead to more survival index predicted and a more convinced conclusion achieved. In addition, to our knowledge, there was no a pooled study to assess the prognostic significance of the neutrophil, lymphocyte, platelet and monocyte counts and LMR in PCa until now.</p><p id="Par29">Given the newly emerging evidence, the goal of this study was to further conduct a systematic review and meta-analysis to reveal the prognostic performance (OS; PFS, progression-free survival; CSS, cancer-specific survival; DMFS, distant metastases-free survival; RFS, recurrence-free survival) of all well-known systemic inflammatory parameters for all patients with PCa and subgroups with different treatments. Pretreatment identification of the level or ratio of these biomarkers may be beneficial for the stratification of prognosis and schedule of medical treatments.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Literature search strategy</title><p id="Par30">This meta-analysis was performed in accordance to the Guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] (no review protocol existed previously).</p><p id="Par31">A systematic literature search was carried out by using PubMed and Cochrane Library databases to assess the relationship between pretreatment systemic inflammatory biomarkers (NLR, PLR, LMR, platelet, lymphocyte, monocyte and neutrophil) and the prognosis of patients with PCa. The current search was updated to August 2018 using the combinations of the following keywords: (1) &#x02018;NLR&#x02019; (or &#x0201c;neutrophil to lymphocyte ratio&#x0201d; or &#x0201c;neutrophil lymphocyte ratio&#x0201d; or &#x0201c;neutrophil-to-lymphocyte&#x0201d;); OR (2) &#x02018;PLR&#x02019; (or &#x0201c;platelet to lymphocyte ratio&#x0201d; or &#x0201c;platelet lymphocyte ratio&#x0201d; or &#x0201c;platelet-to-lymphocyte&#x0201d;; OR (3) &#x02018;LMR&#x02019; (or &#x0201c;lymphocyte monocyte ratio&#x0201d; or &#x0201c;lymphocyte-monocyte ratio&#x0201d; or &#x0201c;lymphocyte to monocyte ratio&#x0201d;); OR (4) &#x02018;platelet&#x02019;; OR (5) &#x02018;lymphocyte&#x02019;; OR (6) &#x02018;monocyte&#x02019;; OR (7) &#x02018;neutrophil&#x02019;; AND &#x02018;prostatic cancer&#x02019; (or &#x0201c;prostate carcinoma&#x0201d; or &#x0201c;prostatic carcinoma&#x0201d;). Furthermore, the reference lists of all identified publications as well as pertinent reviews and meta-analyses were also manually inspected to further screen potentially eligible articles.</p></sec><sec id="Sec4"><title>Selection criteria</title><p id="Par32">Two investigators (HP and XGL) independently screened the candidate publications from the databases. Few disagreements were resolved by discussion and consensus. Literatures were considered eligible if they met the following inclusion criteria: (1) PCa was confirmed by pathological examination; (2) pretreatment (such as chemoradiotherapy, surgery) biomarkers (NLR, PLR, LMR, PLT, lymphocyte, monocyte and neutrophil) were measured by serum-based method and calculated by standard formula with same unit; (3) prognostic related outcomes [such as OS (all-cause mortality), PFS, CSS, DMFS and RFS] were investigated; (4) hazard ratio (HR) with a 95% confidence interval (CI) could be directly obtained or indirectly calculated. Studies were excluded if they were: (1) duplicated literatures; (2) abstracts, letters, reviews, editorials, case reports, comments or non-clinical studies; (3) lack of insufficient data to estimate HR and 95% CI; and (4) literature written in language other than English.</p></sec><sec id="Sec5"><title>Data extraction</title><p id="Par33">Two investigators (HP and XGL) independently extracted the following data: name of first author, publication year, country, sampling time, sample size, study design, patient characteristics (including gender, age, patient status, duration of follow-up), treatment details, cut-off value, HR with 95% CI for survival and associated statistical methods. HR and 95% CI were extracted preferentially from multivariable analyses where available. If not, univariate analysis results were collected. Disagreements were resolved through discussion to reach consensus.</p><p id="Par34">The quality of the included studies was assessed using the Newcastle&#x02013;Ottawa Scale (NOS) [<xref ref-type="bibr" rid="CR25">25</xref>] that consists of three domains: patients selection (0&#x02013;4 points), comparability (0&#x02013;2 points), and outcome assessment (0&#x02013;3 points). Studies with the scores &#x02265;&#x02009;7 were considered to be of high-quality.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par35">Statistical heterogeneity among the studies was tested by using Cochrane&#x02019;s Q (Chi squared) and <italic>I</italic><sup>2</sup> statistic [<xref ref-type="bibr" rid="CR26">26</xref>]. A random-effects model was chosen to calculate the pooled HR and 95% CI for heterogeneous studies (Q test P value &#x0003c;&#x02009;0.10 and <italic>I</italic><sup>2</sup>&#x02009;&#x0003e;&#x02009;50%); otherwise, the fixed-effects model was used. Publication bias was assessed with Egger&#x02019;s linear regression test with funnel plots [<xref ref-type="bibr" rid="CR27">27</xref>]. The influence of publication bias on the overall effect was evaluated by the &#x02018;&#x02018;trim and fill&#x02019;&#x02019; method [<xref ref-type="bibr" rid="CR28">28</xref>]. Sensitivity analysis was performed by recalculating the pooled HRs after omitting one study in each turn from the meta-analysis consecutively (leave-one-out procedure). In addition, a subgroup analysis was also performed according to stratification of ethnicity, sample size, study design, patient status, follow-up time, cut-off, statistical methods and therapy. All statistical analyses were conducted using the STATA software (version 13.0; STATA Corporation, College Station, TX, USA). <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was set as the statistical significance level.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Study characteristics</title><p id="Par36">A flow chart of the literature search is presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The initial search yielded 4280 studies based on the search strategies, in which 1967 were excluded as they were duplicates. After title and abstract screening, 2231 studies were excluded because the following reasons: not PCa (n&#x02009;=&#x02009;166), no prognosis information (n&#x02009;=&#x02009;739), drug therapy effect assessment (n&#x02009;=&#x02009;3), experience lecture (n&#x02009;=&#x02009;31), review (n&#x02009;=&#x02009;25), case (n&#x02009;=&#x02009;30), animal studies (n&#x02009;=&#x02009;539), cell studies (n&#x02009;=&#x02009;395) and molecular studies (n&#x02009;=&#x02009;303). Eighty-two full-text articles were then downloaded to assess their eligibility, in which 54 were further excluded because non-effective data could be collected (n&#x02009;=&#x02009;47), NLR was detected postoperatively (n&#x02009;=&#x02009;1) and NLR was combined with other to form a risk model (n&#x02009;=&#x02009;1) and derived NLR (dNLR) was demined (n&#x02009;=&#x02009;1). Ultimately, 32 studies (n&#x02009;=&#x02009;21,949 participants) were included for subsequent meta-analysis [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>], of which 28 studies including 21,452 participants were included for NLR [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>], 6 studies including 2994 participants for PLR [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], 4 studies including 2594 participants for PLT [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR48">48</xref>], 4 studies including 5133 participants for lymphocyte counts [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], 3 studies including 4843 participants for neutrophil counts [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], 2 studies involving 504 participants for monocyte counts [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] and 1 study involving 214 participants for LMR [<xref ref-type="bibr" rid="CR14">14</xref>]. The study of Shigeta et al. [<xref ref-type="bibr" rid="CR14">14</xref>] had two datasets (training and validation) and both of them were included for assessment of the prognostic value of NLR, LMR and monocyte for PCa. The other characteristics of the included studies are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. NOS scores of all of the selected articles were &#x02265;&#x02009;7, suggesting high quality (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Flow diagram of study identification</p></caption><graphic xlink:href="12935_2019_785_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Characteristics of all the studies included in the meta-analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Year</th><th align="left">Country</th><th align="left">Time</th><th align="left">No.</th><th align="left">Age (years)</th><th align="left">Index and cut-off</th><th align="left">Median follow-up (month)</th><th align="left">Outcome</th></tr></thead><tbody><tr><td align="left">Yasui</td><td char="." align="char">2018</td><td align="left">Japan</td><td align="left">2011&#x02013;2016</td><td char="." align="char">90</td><td align="left">73.7&#x02009;&#x000b1;&#x02009;0.9</td><td align="left">NLR: 3.76</td><td align="left">Unclear</td><td align="left">OS</td></tr><tr><td align="left">Fan</td><td char="." align="char">2018</td><td align="left">China</td><td align="left">2013&#x02013;2017</td><td char="." align="char">104</td><td align="left">72 (65.3&#x02013;77.0)</td><td align="left">NLR: 3</td><td align="left">20.2</td><td align="left">OS, PFS</td></tr><tr><td align="left">Conteduca</td><td char="." align="char">2018</td><td align="left">Italy</td><td align="left">2011&#x02013;2016</td><td char="." align="char">551</td><td align="left">75 (42&#x02013;91)</td><td align="left">NLR: 3</td><td align="left">18.4</td><td align="left">OS, PFS</td></tr><tr><td align="left">Vidal</td><td char="." align="char">2018</td><td align="left">USA</td><td align="left">1991&#x02013;2015</td><td char="." align="char">1826</td><td align="left">61.8&#x02009;&#x000b1;&#x02009;5.9</td><td align="left">NLR; lymphocyte; PLT; neutrophil; PLR</td><td align="left">68</td><td align="left">OS, RFS</td></tr><tr><td align="left">Sun</td><td char="." align="char">2018</td><td align="left">China</td><td align="left">2011&#x02013;2016</td><td char="." align="char">171</td><td align="left">Unclear</td><td align="left">NLR: 2.31; PLR:134</td><td align="left">24</td><td align="left">OS, DFS</td></tr><tr><td align="left">Uemura</td><td char="." align="char">2017</td><td align="left">Japan</td><td align="left">2014&#x02013;2016</td><td char="." align="char">47</td><td align="left">71.0&#x02009;&#x000b1;&#x02009;7.0</td><td align="left">NLR: 3.83</td><td align="left">Unclear</td><td align="left">OS</td></tr><tr><td align="left">Mehra</td><td char="." align="char">2017</td><td align="left">UK</td><td align="left">Unclear</td><td char="." align="char">75</td><td align="left">Unclear</td><td align="left">NLR: 2.6</td><td align="left">25.6</td><td align="left">OS, PFS</td></tr><tr><td align="left">Boegemann</td><td char="." align="char">2017</td><td align="left">USA</td><td align="left">2009&#x02013;2015</td><td char="." align="char">96</td><td align="left">70 (63.0&#x02013;76.3)</td><td align="left">NLR: 5</td><td align="left">20</td><td align="left">OS, PFS</td></tr><tr><td align="left">Pei</td><td char="." align="char">2017</td><td align="left">China</td><td align="left">2013&#x02013;2017</td><td char="." align="char">111</td><td align="left">71 (43&#x02013;86)</td><td align="left">NLR: 3.3</td><td align="left">16</td><td align="left">OS, PFS</td></tr><tr><td align="left">Buttigliero</td><td char="." align="char">2017</td><td align="left">Italy</td><td align="left">Unclear</td><td char="." align="char">110</td><td align="left">Unclear</td><td align="left">NLR: 3</td><td align="left">31.7</td><td align="left">OS, PFS</td></tr><tr><td align="left">Wang</td><td char="." align="char">2017</td><td align="left">China</td><td align="left">2010&#x02013;2014</td><td char="." align="char">290</td><td align="left">71 (65&#x02013;77)</td><td align="left">Monocyte:0.425</td><td align="left">37.0</td><td align="left">OS, PFS</td></tr><tr><td align="left">Jang</td><td char="." align="char">2016</td><td align="left">Korea</td><td align="left">2000&#x02013;2010</td><td char="." align="char">2067</td><td align="left">66 (61&#x02013;70)</td><td align="left">NLR:1.76; lymphocyte, neutrophil</td><td align="left">78</td><td align="left">OS, RFS, CSS</td></tr><tr><td align="left">Lolli</td><td char="." align="char">2016</td><td align="left">Italy</td><td align="left">2011&#x02013;2015</td><td char="." align="char">230</td><td align="left">74 (45&#x02013;90)</td><td align="left">NLR: 3; PLR:210</td><td align="left">29</td><td align="left">OS</td></tr><tr><td align="left">Shigeta</td><td char="." align="char">2016</td><td align="left">Japan</td><td align="left">2007&#x02013;2015</td><td char="." align="char">108<break/>106</td><td align="left">71 (57&#x02013;88)<break/>73 (52&#x02013;95)</td><td align="left">NLR: 3.8; LMR: 3.86; monocyte: 0.4</td><td align="left">Unclear</td><td align="left">OS, PFS</td></tr><tr><td align="left">Lee</td><td char="." align="char">2016</td><td align="left">Korea</td><td align="left">Unclear</td><td char="." align="char">1367</td><td align="left">65.6 (45&#x02013;82)</td><td align="left">NLR: 2.5</td><td align="left">57</td><td align="left">RFS</td></tr><tr><td align="left">Wang</td><td char="." align="char">2016</td><td align="left">China</td><td align="left">2010&#x02013;2014</td><td char="." align="char">290</td><td align="left">75 (67&#x02013;79)</td><td align="left">Lymphocyte; PLT:190.5; PLR:117.58</td><td align="left">37</td><td align="left">OS, PFS, CSS</td></tr><tr><td align="left">Langsenlehner</td><td char="." align="char">2015</td><td align="left">Austria</td><td align="left">1999&#x02013;2007</td><td char="." align="char">415</td><td align="left">66.9&#x02009;&#x000b1;&#x02009;7.2</td><td align="left">NLR: 5</td><td align="left">87</td><td align="left">OS, PFS, DMFS</td></tr><tr><td align="left">Langsenlehner</td><td char="." align="char">2015</td><td align="left">Austria</td><td align="left">1999&#x02013;2007</td><td char="." align="char">374</td><td align="left">68&#x02009;&#x000b1;&#x02009;7.1</td><td align="left">NLR; PLT; PLR:190</td><td align="left">87</td><td align="left">OS, CSS, DMFS</td></tr><tr><td align="left">Zhang</td><td char="." align="char">2015</td><td align="left">China</td><td align="left">2006&#x02013;2009</td><td char="." align="char">237</td><td align="left">Unclear</td><td align="left">NLR: 2.36</td><td align="left">46.6</td><td align="left">RFS</td></tr><tr><td align="left">Bahig</td><td char="." align="char">2015</td><td align="left">Canada</td><td align="left">2001&#x02013;2014</td><td char="." align="char">950</td><td align="left">Unclear</td><td align="left">NLR; lymphocyte; neutrophil</td><td align="left">44</td><td align="left">OS, RFS</td></tr><tr><td align="left">Lorente</td><td char="." align="char">2015</td><td align="left">UK</td><td align="left">Unclear</td><td char="." align="char">755</td><td align="left">67 (62&#x02013;73)</td><td align="left">NLR: 3</td><td align="left">12.8</td><td align="left">OS, PFS</td></tr><tr><td align="left">Yao</td><td char="." align="char">2015</td><td align="left">Japan</td><td align="left">2008&#x02013;2014</td><td char="." align="char">57</td><td align="left">74 (55&#x02013;91)</td><td align="left">NLR: 3.5</td><td align="left">30</td><td align="left">OS, PFS</td></tr><tr><td align="left">Li</td><td char="." align="char">2015</td><td align="left">China</td><td align="left">2009&#x02013;2012</td><td char="." align="char">103</td><td align="left">Unclear</td><td align="left">PLR:150</td><td align="left">36</td><td align="left">OS</td></tr><tr><td align="left">McLachlan</td><td char="." align="char">2015</td><td align="left">Austria</td><td align="left">2005&#x02013;2012</td><td char="." align="char">42</td><td align="left">Unclear</td><td align="left">NLR:5</td><td align="left">23.1</td><td align="left">OS</td></tr><tr><td align="left">Sharma</td><td char="." align="char">2015</td><td align="left">USA</td><td align="left">1990&#x02013;2007</td><td char="." align="char">8350</td><td align="left">Unclear</td><td align="left">NLR:5</td><td align="left">116.4</td><td align="left">OS, PFS, RFS, CSS</td></tr><tr><td align="left">Templeton</td><td char="." align="char">2014</td><td align="left">Canada</td><td align="left">2001&#x02013;2011</td><td char="." align="char">357</td><td align="left">71.0 (44.0&#x02013;90.0)</td><td align="left">NLR: 3</td><td align="left">Unclear</td><td align="left">OS</td></tr><tr><td align="left">Sonpavde</td><td char="." align="char">2014</td><td align="left">UK</td><td align="left">2008&#x02013;2010</td><td char="." align="char">848</td><td align="left">Unclear</td><td align="left">NLR:2.5</td><td align="left">Unclear</td><td align="left">OS, RFS</td></tr><tr><td align="left">Nuhn</td><td char="." align="char">2014</td><td align="left">USA</td><td align="left">1998&#x02013;2010</td><td char="." align="char">238</td><td align="left">68.3 (44.6&#x02013;84.5)</td><td align="left">NLR: 3</td><td align="left">15.0</td><td align="left">OS</td></tr><tr><td align="left">Poyet</td><td char="." align="char">2013</td><td align="left">Switzerland</td><td align="left">2008&#x02013;2013</td><td char="." align="char">399</td><td align="left">64.0 (41.0&#x02013;78.0)</td><td align="left">NLR: 2.67</td><td align="left">23.0</td><td align="left">RFS</td></tr><tr><td align="left">Linton</td><td char="." align="char">2013</td><td align="left">Austria</td><td align="left">2007&#x02013;2009</td><td char="." align="char">184</td><td align="left">Unclear</td><td align="left">NLR: 5</td><td align="left">Unclear</td><td align="left">OS</td></tr><tr><td align="left">Shafique</td><td char="." align="char">2012</td><td align="left">UK</td><td align="left">2000&#x02013;2007</td><td char="." align="char">897</td><td align="left">Unclear</td><td align="left">NLR: 5</td><td align="left">30</td><td align="left">OS</td></tr><tr><td align="left">Yamada</td><td char="." align="char">2011</td><td align="left">Japan</td><td align="left">1998&#x02013;2006</td><td char="." align="char">104</td><td align="left">74.2&#x02009;&#x000b1;&#x02009;7.4</td><td align="left">PLT</td><td align="left">43</td><td align="left">CSS</td></tr></tbody></table><table-wrap-foot><p><italic>OS</italic> overall survival, <italic>CSS</italic> cancer-specific survival, <italic>PFS</italic> progression-free survival, <italic>DMFS</italic> distant metastases-free survival, <italic>RFS</italic> recurrence-free survival, <italic>PLR</italic> platelet to lymphocyte ratio, <italic>NLR</italic> neutrophil to lymphocyte ratios, <italic>LMR</italic> lymphocyte to monocyte ratio, <italic>PLT</italic> platelet</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Quality assessment scale for 32 studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Study</th><th align="left" colspan="4">Selection</th><th align="left" colspan="2">Comparability</th><th align="left" colspan="3">Outcome</th><th align="left" rowspan="3">Total scores</th></tr><tr><th align="left" rowspan="2">Representativeness of the exposed cohort</th><th align="left" rowspan="2">Selection of the non-exposed cohort</th><th align="left" rowspan="2">Assessment of exposure</th><th align="left" rowspan="2">Outcome not present at start of study</th><th align="left" colspan="2">Comparability of cohorts on the basis</th><th align="left" rowspan="2">Assessment of outcome</th><th align="left" rowspan="2">Follow-up long enough for outcome</th><th align="left" rowspan="2">Adequacy of follow-up</th></tr><tr><th align="left">Design</th><th align="left">Analysis</th></tr></thead><tbody><tr><td align="left">Yasui</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Fan</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">9</td></tr><tr><td align="left">Conteduca</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">9</td></tr><tr><td align="left">Vidal</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Sun</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Uemura</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Mehra</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">9</td></tr><tr><td align="left">Boegemann</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Pei</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Buttigliero</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Wang</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Jang</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Lolli</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Shigeta</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Lee</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Wang</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Langsenlehner</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Langsenlehner</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Zhang</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Bahig</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Lorente</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">9</td></tr><tr><td align="left">Yao</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Li</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">McLachlan</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Sharma</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Templeton</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Sonpavde</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Nuhn</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr><tr><td align="left">Poyet</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">7</td></tr><tr><td align="left">Linton</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">9</td></tr><tr><td align="left">Shafique</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">9</td></tr><tr><td align="left">Yamada</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left"/><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td char="." align="char">8</td></tr></tbody></table><table-wrap-foot><p>A positive result on any one of them was counted as one point</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>Association between NLR and PCa survival</title><p id="Par37">Twenty-five studies with 26 datasets evaluated the association between pretreatment NLR and OS in PCa patients. A significant heterogeneity was present among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;83.4%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and thus a random-effects model was chosen to pool the study results. The synthesized estimates analysis showed that patients with elevated NLR had significantly shorter OS (HR&#x02009;=&#x02009;1.55, 95% CI 1.37&#x02013;1.76, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Forest plots of the significant correlations of neutrophil to lymphocyte ratio with survival. <bold>a</bold> Overall survival; <bold>b</bold> progression-free survival; <bold>c</bold> recurrence-free survival. Squares are hazard ratio (HR); horizontal lines are 95% confidence intervals (CI); blue diamond indicates the pooled HR estimate with its 95% CI</p></caption><graphic xlink:href="12935_2019_785_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Overview of pooled results of the prognostic value of hematologic parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Outcome</th><th align="left">No.</th><th align="left">HR</th><th align="left">95% CI</th><th align="left">
<italic>P</italic>
</th><th align="left">I-squared (%)</th><th align="left">
<italic>P</italic>
<sub>H</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="5">NLR</td><td align="left">OS</td><td char="." align="char">26</td><td char="." align="char">1.55</td><td align="left">1.37&#x02013;1.76</td><td char="." align="char">0.000</td><td char="." align="char">83.0</td><td char="." align="char">0.000</td></tr><tr><td align="left">CSS</td><td char="." align="char">4</td><td char="." align="char">1.14</td><td align="left">0.89&#x02013;1.45</td><td char="." align="char">0.297</td><td char="." align="char">61.5</td><td char="." align="char">0.050</td></tr><tr><td align="left">PFS</td><td char="." align="char">12</td><td char="." align="char">1.62</td><td align="left">1.29&#x02013;2.04</td><td char="." align="char">0.000</td><td char="." align="char">67.6</td><td char="." align="char">0.000</td></tr><tr><td align="left">DMFS</td><td char="." align="char">2</td><td char="." align="char">1.81</td><td align="left">0.55&#x02013;6.01</td><td char="." align="char">0.330</td><td char="." align="char">92.3</td><td char="." align="char">0.000</td></tr><tr><td align="left">RFS</td><td char="." align="char">6</td><td char="." align="char">1.12</td><td align="left">1.04&#x02013;1.20</td><td char="." align="char">0.002</td><td char="." align="char">0.0</td><td char="." align="char">0.560</td></tr><tr><td align="left" rowspan="2">PLR</td><td align="left">OS</td><td char="." align="char">6</td><td char="." align="char">1.72</td><td align="left">1.36&#x02013;2.18</td><td char="." align="char">0.000</td><td char="." align="char">0.0</td><td char="." align="char">0.575</td></tr><tr><td align="left">CSS</td><td char="." align="char">3</td><td char="." align="char">1.56</td><td align="left">0.82&#x02013;2.97</td><td char="." align="char">1.000</td><td char="." align="char">78.7</td><td char="." align="char">0.009</td></tr><tr><td align="left" rowspan="2">PLT</td><td align="left">OS</td><td char="." align="char">3</td><td char="." align="char">1.00</td><td align="left">0.98&#x02013;1.02</td><td char="." align="char">0.910</td><td char="." align="char">59.3</td><td char="." align="char">0.086</td></tr><tr><td align="left">CSS</td><td char="." align="char">4</td><td char="." align="char">1.00</td><td align="left">0.99&#x02013;1.01</td><td char="." align="char">0.850</td><td char="." align="char">15.4</td><td char="." align="char">0.315</td></tr><tr><td align="left" rowspan="2">LMR</td><td align="left">OS</td><td char="." align="char">2</td><td char="." align="char">2.27</td><td align="left">1.76&#x02013;2.94</td><td char="." align="char">0.000</td><td char="." align="char">27.8</td><td char="." align="char">0.239</td></tr><tr><td align="left">PFS</td><td char="." align="char">2</td><td char="." align="char">2.18</td><td align="left">1.58&#x02013;3.02</td><td char="." align="char">0.000</td><td char="." align="char">0.0</td><td char="." align="char">0.460</td></tr><tr><td align="left" rowspan="3">Lymphocyte</td><td align="left">OS</td><td char="." align="char">4</td><td char="." align="char">0.96</td><td align="left">0.83&#x02013;1.10</td><td char="." align="char">0.710</td><td char="." align="char">0.0</td><td char="." align="char">0.529</td></tr><tr><td align="left">CSS</td><td char="." align="char">3</td><td char="." align="char">0.85</td><td align="left">0.66&#x02013;1.09</td><td char="." align="char">0.190</td><td char="." align="char">0.0</td><td char="." align="char">0.523</td></tr><tr><td align="left">RFS</td><td char="." align="char">2</td><td char="." align="char">1.06</td><td align="left">0.96&#x02013;1.16</td><td char="." align="char">0.260</td><td char="." align="char">0.0</td><td char="." align="char">0.824</td></tr><tr><td align="left" rowspan="3">Neutrophil</td><td align="left">OS</td><td char="." align="char">3</td><td char="." align="char">1.10</td><td align="left">1.03&#x02013;1.18</td><td char="." align="char">0.006</td><td char="." align="char">0.0</td><td char="." align="char">0.604</td></tr><tr><td align="left">CSS</td><td char="." align="char">2</td><td char="." align="char">1.12</td><td align="left">0.99&#x02013;1.25</td><td char="." align="char">0.065</td><td char="." align="char">0.0</td><td char="." align="char">0.771</td></tr><tr><td align="left">RFS</td><td char="." align="char">2</td><td char="." align="char">1.03</td><td align="left">0.98&#x02013;1.09</td><td char="." align="char">0.188</td><td char="." align="char">0.0</td><td char="." align="char">0.421</td></tr><tr><td align="left" rowspan="2">Monocyte</td><td align="left">OS</td><td char="." align="char">3</td><td char="." align="char">2.25</td><td align="left">1.67&#x02013;3.05</td><td char="." align="char">0.000</td><td char="." align="char">1.54</td><td char="." align="char">0.463</td></tr><tr><td align="left">PFS</td><td char="." align="char">3</td><td char="." align="char">1.75</td><td align="left">1.36&#x02013;2.25</td><td char="." align="char">0.000</td><td char="." align="char">33.2</td><td char="." align="char">0.224</td></tr></tbody></table><table-wrap-foot><p>OS, overall survival; CSS, cancer-specific survival; PFS, progression-free survival; DMFS, distant metastases-free survival; RFS, recurrence-free survival; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PLT, platelet; HR, hazard ratio; CI, confidence intervals; <italic>P</italic><sub>H</sub>, heterogeneity of <italic>P</italic>-value</p></table-wrap-foot></table-wrap>
</p><p id="Par38">There were 4 studies examined the relationship of pretreatment NLR with CSS in PCa patients. A significant heterogeneity was detected among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;61.5%, <italic>P</italic>&#x02009;=&#x02009;0.05) and thus a random-effects model was applied. The estimated pooled HR (95% CI) of 1.14 (95% CI 0.89&#x02013;1.45, <italic>P</italic>&#x02009;=&#x02009;0.297) in 3 studies indicated that patients with an elevated NLR were not associated with shorter CSS after treatment (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par39">Eleven studies with 12 datasets analyzed the pretreatment NLR for predicting the PFS of PCa after treatment. A random-effects model was adopted to pool the study results because the <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;67.6% and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. The pooled estimates analysis predicted PFS was significantly lower in PCa patients with an elevated NLR (random: HR&#x02009;=&#x02009;1.62; 95% CI 1.29&#x02013;2.04, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par40">There were 2 studies to investigate the relationship between pretreatment NLR and DMFS in PCa patients. The Cochran&#x02019;s Q-test resulted in a <italic>P</italic> value&#x02009;&#x0003c;&#x02009;0.001 and the corresponding <italic>I</italic><sup>2</sup> was 92.3%, indicating that there was significant heterogeneity among studies. A random-effects model analysis demonstrated no statistically significant difference in DMFS of patients with higher or lower NLR (HR&#x02009;=&#x02009;1.81; 95% CI 0.55&#x02013;6.01, <italic>P</italic>&#x02009;=&#x02009;0.330; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par41">Six studies analyzed the relationship between pretreatment NLR and RFS in PCa patients. There was no evidence of heterogeneity among studies because the Cochran&#x02019;s Q-test P-value was 0.560 and the corresponding <italic>I</italic><sup>2</sup> was 0%. A fixed-effects model analysis demonstrated the higher level of NLR indicated unfavorable RFS (HR&#x02009;=&#x02009;1.12; 95% CI 1.04&#x02013;1.20, <italic>P</italic>&#x02009;=&#x02009;0.002) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec10"><title>Association between PLR and PCa survival</title><p id="Par42">Six studies evaluated the association between pretreatment PLR and OS in PCa patients. No significant heterogeneity was present among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%, <italic>P</italic>&#x02009;=&#x02009;0.575) and thus a fixed-effects model was chosen. The pooled analysis showed that higher level of PLR was associated with shorter OS (HR&#x02009;=&#x02009;1.72; 95% CI 1.36&#x02013;2.18, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Forest plots of the significant correlation of platelet to lymphocyte ratio with overall survival. Squares are hazard ratio (HR); horizontal lines are 95% confidence intervals (CI); blue diamond indicates the pooled HR estimate with its 95% CI</p></caption><graphic xlink:href="12935_2019_785_Fig3_HTML" id="MO3"/></fig>
</p><p id="Par43">There were 3 studies examined the relationship of pretreatment PLR with CSS in PCa patients. A significant heterogeneity was detected among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;78.7%, <italic>P</italic>&#x02009;=&#x02009;0.009) and thus a random-effects model was applied. The estimated pooled HR (95% CI) of 1.56 (95% CI 0.82&#x02013;2.97, <italic>P</italic>&#x02009;=&#x02009;0.174) in 3 studies indicated that patients with an elevated PLR were not associated with shorter CSS after treatment (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec11"><title>Association between LMR and PCa survival</title><p id="Par44">One study with 2 datasets analyzed the pretreatment LMR for predicting the OS of PCa after treatment. No significant heterogeneity was present among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;27.8%, <italic>P&#x02009;</italic>=&#x02009;0.239) and thus a fixed-effects model was chosen. The pooled analysis showed that higher level of LMR was associated with more favorable OS (HR&#x02009;=&#x02009;2.27; 95% CI 1.76&#x02013;2.94, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Forest plots of the significant correlation of lymphocyte to monocyte ratio with survival. <bold>a</bold> Overall survival; <bold>b</bold> progression-free survival. Squares are hazard ratio (HR); horizontal lines are 95% confidence intervals (CI); blue diamond indicates the pooled HR estimate with its 95% CI</p></caption><graphic xlink:href="12935_2019_785_Fig4_HTML" id="MO4"/></fig>
</p><p id="Par45">One study with 2 datasets analyzed the pretreatment LMR for predicting the PFS of PCa after treatment. No significant heterogeneity was present among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;27.8%, <italic>P</italic>&#x02009;=&#x02009;0.460) and thus a fixed-effects model was chosen. The pooled analysis showed that higher level of LMR was associated with longer PFS (HR&#x02009;=&#x02009;2.18; 95% CI 1.58&#x02013;3.02, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec12"><title>Association between PLT and PCa survival</title><p id="Par46">Three studies evaluated the association between pretreatment PLT and OS in PCa patients. There was evidence of heterogeneity among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;56.1%, P&#x02009;=&#x02009;0.086) and thus a random-effects model was chosen. The pooled analysis showed that pretreatment PLT was not associated with OS (HR&#x02009;=&#x02009;1.00; 95% CI 0.98&#x02013;1.02, <italic>P</italic>&#x02009;=&#x02009;0.910; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par47">Four studies evaluated the association between pretreatment PLT and CSS in PCa patients. There was no evidence of heterogeneity among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;15.4%, <italic>P</italic>&#x02009;=&#x02009;0.315) and thus a fixed-effects model was chosen. The pooled analysis showed that pretreatment PLT was not associated with CSS (HR&#x02009;=&#x02009;1.00; 95% CI 0.99&#x02013;1.01, <italic>P</italic>&#x02009;=&#x02009;0.850; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec13"><title>Association between lymphocyte counts and PCa survival</title><p id="Par48">Four articles studied the association between pretreatment lymphocyte counts and OS in PCa patients. There was no evidence of heterogeneity among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%, <italic>P</italic>&#x02009;=&#x02009;0.710) and thus a fixed-effects model was chosen. The pooled analysis showed that pretreatment lymphocyte counts could not predict the OS (HR&#x02009;=&#x02009;0.96; 95% CI 0.83&#x02013;1.10, <italic>P</italic>&#x02009;=&#x02009;0.529; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par49">Three articles provided CSS as the primary outcome. There was no evidence of heterogeneity among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%, <italic>P</italic>&#x02009;=&#x02009;0.523) and thus a fixed-effects model was chosen. The pooled analysis showed that the higher lymphocyte counts also could not predict the CSS (HR&#x02009;=&#x02009;0.85; 95% CI 0.66&#x02013;1.09, <italic>P</italic>&#x02009;=&#x02009;0.190; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par50">Two articles studied the association between pretreatment lymphocyte counts and RFS in PCa patients. There was no evidence of heterogeneity among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%, <italic>P&#x02009;</italic>=&#x02009;0.824) and thus a fixed-effects model was chosen. The pooled analysis showed that pretreatment lymphocyte counts were similarly not associated with RFS (HR&#x02009;=&#x02009;1.06; 95% CI 0.96&#x02013;1.16, <italic>P</italic>&#x02009;=&#x02009;0.260; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec14"><title>Association between neutrophil counts and PCa survival</title><p id="Par51">Three articles studied the association between pretreatment neutrophil counts and OS in PCa patients. There was no evidence of heterogeneity among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%, <italic>P</italic>&#x02009;=&#x02009;0.604) and thus a fixed-effects model was chosen. The pooled analysis showed that patients with higher pretreatment neutrophil counts were expected to have shorter OS (HR&#x02009;=&#x02009;1.10; 95% CI 1.03&#x02013;1.18, <italic>P</italic>&#x02009;=&#x02009;0.006) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Forest plots of the significant correlation of neutrophil counts with overall survival. Squares are hazard ratio (HR); horizontal lines are 95% confidence intervals (CI); blue diamond indicates the pooled HR estimate with its 95% CI</p></caption><graphic xlink:href="12935_2019_785_Fig5_HTML" id="MO5"/></fig>
</p><p id="Par52">Two articles provided sufficient data on CSS outcome for the pooled estimate of neutrophil counts in PCa patients. There was no evidence of heterogeneity among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%, <italic>P&#x02009;</italic>=&#x02009;0.771) and thus a fixed-effects model was chosen. The pooled analysis showed that the higher neutrophil counts did not predict poorer CSS (HR&#x02009;=&#x02009;1.12; 95% CI 0.99&#x02013;1.25, <italic>P</italic>&#x02009;=&#x02009;0.065) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par53">Two articles studied the association between pretreatment neutrophil counts and RFS in PCa patients. There was no evidence of heterogeneity among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%, <italic>P</italic>&#x02009;=&#x02009;0.942) and thus a fixed-effects model was chosen. The pooled analysis showed no significant difference in neutrophil counts observed between patients with higher and lower pretreatment neutrophil counts (HR&#x02009;=&#x02009;1.03; 95% CI 0.98&#x02013;1.09, <italic>P</italic>&#x02009;=&#x02009;0.188; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec15"><title>Association between monocyte counts and PCa survival</title><p id="Par54">Two articles with three datasets studied the association between pretreatment monocyte counts and OS in PCa patients. There was no evidence of heterogeneity among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%, <italic>P&#x02009;</italic>=&#x02009;0.463) and thus a fixed-effects model was chosen. The pooled analysis showed that patients with higher pretreatment monocyte counts were expected to have shorter OS (HR&#x02009;=&#x02009;2.25; 95% CI 1.67&#x02013;3.05, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Forest plots of the significant correlation of monocyte counts with survival. <bold>a</bold> Overall survival; <bold>b</bold> progression-free survival. Squares are hazard ratio (HR); horizontal lines are 95% confidence intervals (CI); blue diamond indicates the pooled HR estimate with its 95% CI</p></caption><graphic xlink:href="12935_2019_785_Fig6_HTML" id="MO6"/></fig>
</p><p id="Par55">Two articles with three datasets provided sufficient data on PFS outcome for the pooled estimate of monocyte counts in PCa patients. There was no evidence of heterogeneity among studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;33.2%, <italic>P</italic>&#x02009;=&#x02009;0.224) and thus a fixed-effects model was chosen. The pooled analysis showed that the higher monocyte counts predicted poorer PFS (HR&#x02009;=&#x02009;1.75; 95% CI 1.36&#x02013;2.25, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec16"><title>Publication bias</title><p id="Par56">The above analysis showed that NLR, PLR, neutrophil and monocyte counts were hematologic parameters significantly associated with prognosis (NLR: OS, PFS and RFS; PLR: OS; neutrophil counts: OS; monocyte counts: OS and PFS). Therefore, funnel plots of the pooled analysis of these 4 parameters were constructed to examine whether there was a publication bias. The results revealed that the publication bias was present in NLR for OS (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a), but not in NLR for PFS (<italic>P</italic>&#x02009;=&#x02009;0.189) and RFS (<italic>P</italic>&#x02009;=&#x02009;0.398); PLR for OS (<italic>P</italic>&#x02009;=&#x02009;0.218); neutrophil counts for OS (<italic>P</italic>&#x02009;=&#x02009;0.454); monocyte counts for OS (<italic>P</italic>&#x02009;=&#x02009;0.173) and PFS (<italic>P</italic>&#x02009;=&#x02009;0.137). Subsequently, a trim-and-fill method was performed to explore the influence of publication bias on the effect estimate. The filled meta-analysis still indicated there was still a significant association between pretreatment NLR and OS (HR&#x02009;=&#x02009;1.21; 95% CI 1.07&#x02013;1.37, <italic>P</italic>&#x02009;=&#x02009;0.007) (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>b). Only one study was included for LMR and thus publication bias was not present.<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Funnel plot for the assessment of potential publication bias. <bold>a</bold> Egger&#x02019;s funnel plot for overall survival of NLR; <bold>b</bold> Trim-and-fill funnel plot for overall survival of NLR. <italic>SND</italic> standard normal deviation, <italic>s.e.</italic> standard error, <italic>CI</italic> confidence intervals</p></caption><graphic xlink:href="12935_2019_785_Fig7_HTML" id="MO7"/></fig>
</p></sec><sec id="Sec17"><title>Sensitivity analyses</title><p id="Par57">Sensitivity analysis was performed by assessing the potential impact of individual dataset on the pooled data. The results showed that pooled HR was not significantly altered when each single study was deleted every time (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>).<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>Sensitivity analysis. The horizontal axis was ln(HR). The two ends of every broken line represent the 95% CI</p></caption><graphic xlink:href="12935_2019_785_Fig8_HTML" id="MO8"/></fig>
</p></sec><sec id="Sec18"><title>Subgroup analysis</title><p id="Par58">The subgroup analyses according to ethnicity, sample size, study design, patient status, follow-up time, cut-off, statistical methods and therapy were only performed for NLR and PLR due to limited literatures. The results showed that elevated NLR predicted poor prognosis in almost all of stratified categories except localized PCa (HR&#x02009;=&#x02009;1.10; 95% CI 0.93&#x02013;1.31, <italic>P</italic>&#x02009;=&#x02009;0.274), surgery (HR&#x02009;=&#x02009;1.12; 95% CI 0.99&#x02013;1.26, <italic>P</italic>&#x02009;=&#x02009;0.072), radiotherapy (HR&#x02009;=&#x02009;1.10; 95% CI 0.95&#x02013;1.27, <italic>P</italic>&#x02009;=&#x02009;0.198) for OS; and surgery (HR&#x02009;=&#x02009;1.64; 95% CI 0.51&#x02013;5.26, <italic>P</italic>&#x02009;=&#x02009;0.404), prospective study design for PFS (HR&#x02009;=&#x02009;1.42; 95% CI 0.89&#x02013;2.26, <italic>P</italic>&#x02009;=&#x02009;0.144) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The high PLR also predicted poor OS in almost all of stratified categories except PCa (HR&#x02009;=&#x02009;2.01; 95% CI 1.42&#x02013;2.87, <italic>P</italic>&#x02009;=&#x02009;0.068) and mCRPC (HR&#x02009;=&#x02009;1.41; 95% CI 0.98&#x02013;2.04, <italic>P</italic>&#x02009;=&#x02009;0.068) (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Subgroup analyses of NLR for OS and PFS</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="6">OS</th><th align="left" colspan="5">PFS</th><th align="left" rowspan="2">
<italic>P</italic>
<sub>H</sub>
</th></tr><tr><th align="left">No.</th><th align="left">HR</th><th align="left">95% CI</th><th align="left">
<italic>P</italic>
</th><th align="left">I-squared</th><th align="left">
<italic>P</italic>
<sub>H</sub>
</th><th align="left">No.</th><th align="left">HR</th><th align="left">95% CI</th><th align="left">
<italic>P</italic>
</th><th align="left">I-squared</th></tr></thead><tbody><tr><td align="left" colspan="13">Ethnicity</td></tr><tr><td align="left">&#x000a0;Asian</td><td char="." align="char">10</td><td char="." align="char">1.83</td><td align="left">1.52&#x02013;2.21</td><td align="left">0.000</td><td align="left">0.0%</td><td align="left">0.715</td><td align="left">5</td><td align="left">1.59</td><td align="left">1.23&#x02013;2.06</td><td align="left">0.000</td><td align="left">0.0%</td><td align="left">0.436</td></tr><tr><td align="left">&#x000a0;Other</td><td char="." align="char">16</td><td char="." align="char">1.45</td><td align="left">1.26&#x02013;1.66</td><td align="left">0.000</td><td align="left">86.6%</td><td align="left">0.000</td><td align="left">7</td><td align="left">1.62</td><td align="left">1.18&#x02013;2.23</td><td align="left">0.003</td><td align="left">79.7%</td><td align="left">0.000</td></tr><tr><td align="left" colspan="13">Patients status</td></tr><tr><td align="left">&#x000a0;mCRPC</td><td char="." align="char">13</td><td char="." align="char">1.70</td><td align="left">1.52&#x02013;1.90</td><td align="left">0.000</td><td align="left">17.7%</td><td align="left">0.265</td><td align="left">6</td><td align="left">1.62</td><td align="left">1.33&#x02013;1.98</td><td align="left">0.000</td><td align="left">45.3%</td><td align="left">0.140</td></tr><tr><td align="left">&#x000a0;CRPC</td><td char="." align="char">5</td><td char="." align="char">1.86</td><td align="left">1.40&#x02013;2.48</td><td align="left">0.000</td><td align="left">0.0%</td><td align="left">0.716</td><td align="left">4</td><td align="left">1.76</td><td align="left">1.18&#x02013;2.62</td><td align="left">0.006</td><td align="left">28.5%</td><td align="left">0.221</td></tr><tr><td align="left">&#x000a0;Localized PCa</td><td char="." align="char">3</td><td char="." align="char">1.10</td><td align="left">0.93&#x02013;1.31</td><td align="left">0.274</td><td align="left">71.7%</td><td align="left">0.029</td><td align="left">1</td><td align="left">3.09</td><td align="left">1.64&#x02013;5.82</td><td align="left">0.000</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;All PCa</td><td char="." align="char">5</td><td char="." align="char">1.20</td><td align="left">1.02&#x02013;1.41</td><td align="left">0.026</td><td align="left">53.5%</td><td align="left">0.072</td><td align="left">1</td><td align="left">0.84</td><td align="left">0.74&#x02013;1.19</td><td align="left">0.603</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="13">Sample size</td></tr><tr><td align="left">&#x000a0;&#x02264;&#x02009;300</td><td char="." align="char">15</td><td char="." align="char">1.73</td><td align="left">1.40&#x02013;2.16</td><td align="left">0.002</td><td align="left">59.6%</td><td align="left">0.598</td><td align="left">9</td><td align="left">1.51</td><td align="left">1.13&#x02013;2.01</td><td align="left">0.005</td><td align="left">58.7%</td><td align="left">0.013</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;300</td><td char="." align="char">11</td><td char="." align="char">1.45</td><td align="left">1.23&#x02013;1.71</td><td align="left">0.000</td><td align="left">89.5%</td><td align="left">0.000</td><td align="left">3</td><td align="left">1.88</td><td align="left">1.32&#x02013;2.67</td><td align="left">0.000</td><td align="left">73.5%</td><td align="left">0.023</td></tr><tr><td align="left" colspan="13">Follow time</td></tr><tr><td align="left">&#x000a0;&#x02264;&#x02009;30</td><td char="." align="char">12</td><td char="." align="char">1.74</td><td align="left">1.55&#x02013;1.95</td><td align="left">0.000</td><td align="left">0.0%</td><td align="left">0.748</td><td align="left">7</td><td align="left">1.77</td><td align="left">1.39&#x02013;2.27</td><td align="left">0.000</td><td align="left">45.3%</td><td align="left">0.089</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;30</td><td char="." align="char">7</td><td char="." align="char">1.15</td><td align="left">1.02&#x02013;1.30</td><td align="left">0.020</td><td align="left">75.2%</td><td align="left">0.000</td><td align="left">3</td><td align="left">1.59</td><td align="left">0.77&#x02013;3.28</td><td align="left">0.212</td><td align="left">84.8%</td><td align="left">0.001</td></tr><tr><td align="left">&#x000a0;Unclear</td><td char="." align="char">7</td><td char="." align="char">1.58</td><td align="left">1.39&#x02013;1.80</td><td align="left">0.000</td><td align="left">0.0%</td><td align="left">0.430</td><td align="left">2</td><td align="left">1.36</td><td align="left">1.00&#x02013;1.88</td><td align="left">0.061</td><td align="left">0.0%</td><td align="left">0.700</td></tr><tr><td align="left" colspan="13">Cut-off</td></tr><tr><td align="left">&#x000a0;&#x02264;&#x02009;3</td><td char="." align="char">10</td><td char="." align="char">1.75</td><td align="left">1.57&#x02013;1.97</td><td align="left">0.000</td><td align="left">0.0%</td><td align="left">0.014</td><td align="left">5</td><td align="left">1.81</td><td align="left">1.36&#x02013;2.42</td><td align="left">0.000</td><td align="left">51.2%</td><td align="left">0.085</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;3</td><td char="." align="char">12</td><td char="." align="char">1.63</td><td align="left">1.32&#x02013;2.00</td><td align="left">0.000</td><td align="left">53.8%</td><td align="left">0.444</td><td align="left">7</td><td align="left">1.50</td><td align="left">1.09&#x02013;2.07</td><td align="left">0.014</td><td align="left">68.5%</td><td align="left">0.004</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">4</td><td char="." align="char">1.14</td><td align="left">0.97&#x02013;1.34</td><td align="left">0.101</td><td align="left">88.5%</td><td align="left">0.000</td><td align="left">0</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="13">Study design</td></tr><tr><td align="left">&#x000a0;Retrospective</td><td char="." align="char">21</td><td char="." align="char">1.63</td><td align="left">1.39&#x02013;1.91</td><td align="left">0.000</td><td align="left">84.0%</td><td align="left">0.000</td><td align="left">9</td><td align="left">1.74</td><td align="left">1.42&#x02013;2.13</td><td align="left">0.000</td><td align="left">25.3%</td><td align="left">0.219</td></tr><tr><td align="left">&#x000a0;Prospective</td><td char="." align="char">5</td><td char="." align="char">1.36</td><td align="left">1.10&#x02013;1.68</td><td align="left">0.005</td><td align="left">66.7%</td><td align="left">0.017</td><td align="left">3</td><td align="left">1.42</td><td align="left">0.89&#x02013;2.26</td><td align="left">0.144</td><td align="left">84.3%</td><td align="left">0.002</td></tr><tr><td align="left" colspan="13">Statistical method</td></tr><tr><td align="left">&#x000a0;Multivariable</td><td char="." align="char">22</td><td char="." align="char">1.54</td><td align="left">1.34&#x02013;1.77</td><td align="left">0.000</td><td align="left">79.5%</td><td align="left">0.000</td><td align="left">10</td><td align="left">1.65</td><td align="left">1.22&#x02013;2.24</td><td align="left">0.001</td><td align="left">66.3%</td><td align="left">0.002</td></tr><tr><td align="left">&#x000a0;Univariable</td><td char="." align="char">4</td><td char="." align="char">1.56</td><td align="left">1.17&#x02013;2.10</td><td align="left">0.003</td><td align="left">85.9%</td><td align="left">0.000</td><td align="left">2</td><td align="left">1.66</td><td align="left">1.20&#x02013;2.30</td><td align="left">0.002</td><td align="left">74.1%</td><td align="left">0.049</td></tr><tr><td align="left" colspan="13">Therapy</td></tr><tr><td align="left">&#x000a0;Surgery</td><td char="." align="char">5</td><td char="." align="char">1.12</td><td align="left">0.99&#x02013;1.26</td><td align="left">0.072</td><td align="left">72.7%</td><td align="left">0.005</td><td align="left">2</td><td align="left">1.64</td><td align="left">0.51&#x02013;5.26</td><td align="left">0.404</td><td align="left">91.6%</td><td align="left">0.001</td></tr><tr><td align="left">&#x000a0;Chemotherapy</td><td char="." align="char">18</td><td char="." align="char">1.69</td><td align="left">1.53&#x02013;1.84</td><td align="left">0.000</td><td align="left">1.2%</td><td align="left">0.440</td><td align="left">10</td><td align="left">1.64</td><td align="left">1.38&#x02013;1.95</td><td align="left">0.000</td><td align="left">27.8%</td><td align="left">0.188</td></tr><tr><td align="left">&#x000a0;Radiotherapy</td><td char="." align="char">1</td><td char="." align="char">1.10</td><td align="left">0.95&#x02013;1.27</td><td align="left">0.198</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;Others</td><td char="." align="char">2</td><td char="." align="char">1.63</td><td align="left">1.07&#x02013;2.47</td><td align="left">0.022</td><td align="left">0.0%</td><td align="left">0.638</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr></tbody></table><table-wrap-foot><p>OS, overall survival; PFS, progression-free survival; NLR, neutrophil to lymphocyte ratios; mCRPC, metastatic castration-resistant prostate cancer; PCa, prostate cancer; HR, hazard ratio; CI, confidence intervals; <italic>P</italic><sub>H</sub>, heterogeneity of <italic>P</italic>-value</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Subgroup analyses of PLR for OS</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">No.</th><th align="left">HR</th><th align="left">95% CI</th><th align="left">
<italic>P</italic>
</th><th align="left">I-squared</th><th align="left">
<italic>P</italic>
<sub><italic>H</italic></sub>
</th></tr></thead><tbody><tr><td align="left" colspan="7">Ethnicity</td></tr><tr><td align="left">&#x000a0;Asian</td><td char="." align="char">3</td><td char="." align="char">2.01</td><td align="left">1.42&#x02013;2.87</td><td char="." align="char">0.000</td><td align="left">0.0%</td><td align="left">0.623</td></tr><tr><td align="left">&#x000a0;Other</td><td char="." align="char">3</td><td char="." align="char">1.52</td><td align="left">1.11&#x02013;2.09</td><td char="." align="char">0.009</td><td align="left">0.0%</td><td align="left">0.435</td></tr><tr><td align="left" colspan="7">Patients status</td></tr><tr><td align="left">&#x000a0;PCa</td><td char="." align="char">4</td><td char="." align="char">2.01</td><td align="left">1.42&#x02013;2.87</td><td char="." align="char">0.068</td><td align="left">0.0%</td><td align="left">0.623</td></tr><tr><td align="left">&#x000a0;mCRPC</td><td char="." align="char">1</td><td char="." align="char">1.41</td><td align="left">0.98&#x02013;2.04</td><td char="." align="char">0.068</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;Localized PCa</td><td char="." align="char">1</td><td char="." align="char">1.87</td><td align="left">1.02&#x02013;3.42</td><td char="." align="char">0.043</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="7">Sample size</td></tr><tr><td align="left">&#x000a0;&#x02264;&#x02009;300</td><td char="." align="char">4</td><td char="." align="char">1.70</td><td align="left">1.32&#x02013;2.19</td><td char="." align="char">0.000</td><td align="left">0.0%</td><td align="left">0.421</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;300</td><td char="." align="char">2</td><td char="." align="char">1.87</td><td align="left">1.02&#x02013;3.42</td><td char="." align="char">0.043</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="7">Follow time</td></tr><tr><td align="left">&#x000a0;&#x02264;&#x02009;30</td><td char="." align="char">2</td><td char="." align="char">1.49</td><td align="left">1.06&#x02013;2.10</td><td char="." align="char">0.022</td><td align="left">0.0%</td><td align="left">0.425</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;30</td><td char="." align="char">4</td><td char="." align="char">1.96</td><td align="left">1.42&#x02013;2.71</td><td char="." align="char">0.000</td><td align="left">0.0%</td><td align="left">0.615</td></tr><tr><td align="left" colspan="7">Cut&#x02013;off</td></tr><tr><td align="left">&#x000a0;&#x02264;&#x02009;150</td><td char="." align="char">2</td><td char="." align="char">2.01</td><td align="left">1.42&#x02013;2.87</td><td char="." align="char">0.000</td><td align="left">0.0%</td><td align="left">0.655</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;150</td><td char="." align="char">3</td><td char="." align="char">1.52</td><td align="left">1.11&#x02013;2.09</td><td char="." align="char">0.009</td><td align="left">25.7%</td><td align="left">0.261</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">1</td><td char="." align="char">1.00</td><td align="left">1.36&#x02013;2.18</td><td char="." align="char">0.000</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="7">Statistical method</td></tr><tr><td align="left">&#x000a0;Multivariable</td><td char="." align="char">3</td><td char="." align="char">1.75</td><td align="left">1.16&#x02013;2.62</td><td char="." align="char">0.007</td><td align="left">0.0%</td><td align="left">0.763</td></tr><tr><td align="left">&#x000a0;Univariable</td><td char="." align="char">3</td><td char="." align="char">1.78</td><td align="left">1.23&#x02013;2.58</td><td char="." align="char">0.002</td><td align="left">28.7%</td><td align="left">0.246</td></tr><tr><td align="left" colspan="7">Therapy</td></tr><tr><td align="left">&#x000a0;Surgery</td><td char="." align="char">2</td><td char="." align="char">1.87</td><td align="left">1.02&#x02013;3.42</td><td char="." align="char">0.043</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;Chemotherapy</td><td char="." align="char">2</td><td char="." align="char">1.48</td><td align="left">1.09&#x02013;2.01</td><td char="." align="char">0.012</td><td align="left">0.0%</td><td align="left">0.640</td></tr><tr><td align="left">&#x000a0;Radiotherapy</td><td char="." align="char">2</td><td char="." align="char">2.33</td><td align="left">1.46&#x02013;3.69</td><td char="." align="char">0.000</td><td align="left">0.0%</td><td align="left">0.798</td></tr></tbody></table><table-wrap-foot><p>OS, overall survival; PLR, platelet to lymphocyte ratio; mCRPC, metastatic castration-resistant prostate cancer; PCa, prostate cancer; HR, hazard ratio; CI, confidence intervals; <italic>P</italic><sub>H</sub>, heterogeneity of <italic>P</italic>-value</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec19"><title>Discussion</title><p id="Par59">Our present study, for the first time, included 32 studies to comprehensively evaluate the prognostic values of pretreatment systemic inflammatory factors (neutrophil, lymphocyte, platelet and monocyte counts as well as NRL, PLR and LMR) in patients with PCa. The results indicated that a high pretreatment NLR, PLR, neutrophil and monocyte counts predicted inferior OS outcomes; while elevated pretreatment LMR was correlated with favorable OS. In addition, the pooled data provided evidence that the higher NLR and monocyte counts, but lower LMR predicted worse PFS; poor RFS was only associated with pretreatment NLR. The subgroup analysis showed that the higher NLR may be a risk factor for prediction of OS only in patients with mCRPC and undergoing chemotherapy, but for PFS in patients with each status and chemotherapy; however, the higher PLR was only significantly associated with OS in localized PCa, but not mCRPC no matter of which therapy strategy.</p><p id="Par60">Compared with the study of Yin et al. [<xref ref-type="bibr" rid="CR20">20</xref>] (26 vs 14) and Cao et al. (26 vs 21) [<xref ref-type="bibr" rid="CR21">21</xref>] which investigated the prognostic value of NLR for PCa, our study included more recently published literatures (13, 2016&#x02013;2018) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Also, several articles included in Yin et al. [<xref ref-type="bibr" rid="CR20">20</xref>] and Cao et al. [<xref ref-type="bibr" rid="CR21">21</xref>] were excluded because of inconsistent detection method (dNLR, the absolute neutrophil count divided by the difference between white cell and neutrophil counts; not NLR, the absolute neutrophil count divided by the absolute lymphocyte count) [<xref ref-type="bibr" rid="CR53">53</xref>] or HR (95% CI) crudely extracted from the figures by software which may be inaccurate [<xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>]. Thus, our conclusion may be more credible. Although our results seemed not completely similar to other two meta-analysis articles, they all indicated elevated pretreatment NLR was a prognostic predictor of shorter OS in mCRPC, a metastatic PCa. A high NLR indicated the number of neutrophils may increase. There have several studies to demonstrate neutrophilia promoted the metastasis of tumor cells [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. For example, Donati et al. reported neutrophil counts were elevated in premetastatic lungs in a syngenic mouse model using 4T1 tumor cells. Neutrophils may promote 4T1 cell adhesiveness, invasiveness, and migration by secreting cytokine IL-16, while instillation of an IL-16 neutralizing antibody reversed the effects of neutrophil on tumor cells [<xref ref-type="bibr" rid="CR59">59</xref>]. Lu et al. proved the decreased release of C-X-C motif chemokine ligand 8, C-C motif chemokine ligand 2 (CCL2), CCL4, and matrix metalloproteinase-9 in neutrophils hampered the migration and invasion of oral squamous cell carcinoma cells [<xref ref-type="bibr" rid="CR61">61</xref>]. The study of Wculek et al. supported that neutrophil-derived leukotrienes aided the colonization of distant tissue by selectively expanding the sub-pool of cancer cells that retain high tumorigenic potential. Genetic or pharmacologic inhibition of the leukotriene-generating enzyme arachidonate 5-lipoxygenase abrogated the pro-metastatic activity of neutrophils and consequently reduced metastasis [<xref ref-type="bibr" rid="CR62">62</xref>]. Furthermore, there was also evidence to show neutrophilia facilitates the establishment of metastases by suppressing the anti-tumor activity of IL-17-producing &#x003b3;&#x003b4; T lymphocytes [<xref ref-type="bibr" rid="CR63">63</xref>]. Patients with a higher metastatic potential are more prone to die. In line with these studies, we also found pretreatment neutrophilia was an excellent predictor for poor OS.</p><p id="Par61">Compared with the study of Wang et al. [<xref ref-type="bibr" rid="CR22">22</xref>] on PLR, we included another two recently published literatures [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] to expand the study samples (2994 vs 997). As expected, the results were inconsistent and the positive association between elevated PLR and shorter CSS demonstrated by Wang et al. [<xref ref-type="bibr" rid="CR22">22</xref>] was not significant in our study. Only the relationship between a high pretreatment PLR and poor OS remained to be significantly demonstrated in both meta-analyses. Furthermore, we, for the first time, performed the subgroup analysis for PLR and the finding implied the higher PLR was only significantly associated with OS in localized PCa regardless of treatment options, but not mCRPC, suggesting PLR may be a prognosis factor for early stage. This conclusion seemed to be in accordance with the tumor proliferation-promoting roles of increased platelets by releasing platelet-derived growth factor and transforming growth factor [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par62">Monocytes may reflect the formation of tumor-associated macrophages (TAMs). Extensive studies have suggested that monocytes/TAMs exert a pro-tumorigenic effect by the secretion of chitinase-3-like 1 (CHI3L1, YKL-40), interleukin-13 receptor&#x003b1;2 (IL-13R&#x003b1;2) and then facilitating tumor cell invasion and migration [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Thus, monocyte counts have been believed as a clinical prognostic factor for various cancers (including PCa), showing higher infiltration of monocytes predicts poor overall survival [<xref ref-type="bibr" rid="CR14">14</xref>]. The higher monocytes counts may lead to the lower LMR and thus decreased LMR may be correlated with poor OS (in contrast, high LMR predict more favorable outcomes). This hypothesis was demonstrated in our study and several studies of other cancers [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].</p><p id="Par63">This meta-analysis has several limitations that should be acknowledged. First, the majority of eligible studies are retrospective which may carry a greater risk of selection bias. Second, the samples size is still not large. Only articles published in English language were included which may miss some studies with negative results published in native language. There were only 6 studies to be included for subgroup analysis of PLR and only two or three datasets enrolled to evaluate the prognostic significance of LMR and monocytes counts, which may result in the overestimation or underestimation of their prognostic values. Third, these inflammatory indicators are easily affected by the patients&#x02019; basic state such as age, tumor size, histological type, infection, and other inflammatory diseases. Some eligible studies did not describe these in detail that may cause the presence of heterogeneity. Fourth, inflammatory markers were analyzed in isolation of other prognostic markers. Further studies are needed to see their information value and (possible) influence on therapy in combination with clinical and molecular data. Fifth, all the inflammatory biomarkers were independently studied in the included articles. Thus, which or which combination may be more effective still cannot be confirmed in our study. Sixth, the NLR and PLR cutoff values used in the included studies ranged from 1.73 to 5 for NLR and 117.58 to 190 for PLR. This heterogeneity could hinder the application of these ratios in the clinical setting.</p></sec><sec id="Sec20"><title>Conclusion</title><p id="Par64">Our meta-analysis preliminarily draw a conclusion that pretreatment elevated blood-based NLR, PLR, neutrophil and monocyte counts, but lower LMR are associated with worse OS in PCa patients. Detection of NLR, monocyte counts, and LMR may represent an inexpensive and easily available method for recurrence and progression prediction and may provide important supporting information to inform treatment decisions and predict potential treatment outcomes. The higher NLR and PLR may be a predominant risk factor for prognosis prediction for patients with mCRPC and localized PCa, respectively.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>PCa</term><def><p id="Par5">prostate cancer</p></def></def-item><def-item><term>OS</term><def><p id="Par6">overall survival</p></def></def-item><def-item><term>TNM</term><def><p id="Par7">tumor, node, metastasis</p></def></def-item><def-item><term>PSA</term><def><p id="Par8">prostate-specific antigen</p></def></def-item><def-item><term>PLT</term><def><p id="Par9">platelet</p></def></def-item><def-item><term>NLR</term><def><p id="Par10">neutrophil&#x02013;lymphocyte ratio</p></def></def-item><def-item><term>dNLR</term><def><p id="Par11">derived NLR</p></def></def-item><def-item><term>PLR</term><def><p id="Par12">platelet&#x02013;lymphocyte ratio</p></def></def-item><def-item><term>LMR</term><def><p id="Par13">lymphocyte&#x02013;monocyte ratio</p></def></def-item><def-item><term>PFS</term><def><p id="Par14">progression-free survival</p></def></def-item><def-item><term>CSS</term><def><p id="Par15">cancer-specific survival</p></def></def-item><def-item><term>DMFS</term><def><p id="Par16">distant metastases-free survival</p></def></def-item><def-item><term>RFS</term><def><p id="Par17">recurrence-free survival</p></def></def-item><def-item><term>PRISMA</term><def><p id="Par18">Preferred Reporting Items for Systematic Review and Meta-Analysis</p></def></def-item><def-item><term>HR</term><def><p id="Par19">hazard ratio</p></def></def-item><def-item><term>CI</term><def><p id="Par20">confidence interval</p></def></def-item><def-item><term>NOS</term><def><p id="Par21">Newcastle&#x02013;Ottawa Scale</p></def></def-item><def-item><term>CCL2</term><def><p id="Par22">C-C motif chemokine ligand 2</p></def></def-item><def-item><term>CHI3L1</term><def><p id="Par23">chitinase-3-like 1</p></def></def-item><def-item><term>IL-13R&#x003b1;2</term><def><p id="Par24">interleukin-13 receptor&#x003b1;2</p></def></def-item><def-item><term>TAMs</term><def><p id="Par25">tumor-associated macrophages</p></def></def-item></def-list></glossary><ack><title>Authors&#x02019; contributions</title><p>HP and XGL collected, extracted performed quality assessment and analyzed the data; HP conceived, designed this study and wrote the paper. All authors reviewed the final manuscript. Both authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p id="Par65">None.</p></sec><sec id="FPar2" sec-type="COI-statement"><title>Competing interests</title><p id="Par66">The authors declared no potential competing interests with respect to the research, authorship, and/or publication of this article.</p></sec><sec id="FPar3" sec-type="data-availability"><title>Availability of data and materials</title><p id="Par67">The datasets analyzed during the current study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par68">Not applicable.</p></sec><sec id="FPar5"><title>Ethics approval and consent to participate</title><p id="Par69">Not applicable.</p></sec><sec id="FPar6"><title>Funding</title><p id="Par70">The authors received no financial support for the research, authorship, and/or publication of this article.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p id="Par71">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer Statistics, 2017</article-title><source>CA Cancer J Clin</source><year>2017</year><volume>67</volume><issue>1</issue><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">28055103</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name></person-group><article-title>Comparison of clinical and survival characteristics between prostate cancer patients of PSA-based screening and clinical diagnosis in China</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>428</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">29416625</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomioka</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Yoshikawa</surname><given-names>M</given-names></name><name><surname>Miyake</surname><given-names>M</given-names></name><name><surname>Anai</surname><given-names>S</given-names></name><name><surname>Chihara</surname><given-names>Y</given-names></name><name><surname>Okajima</surname><given-names>E</given-names></name><name><surname>Hirayama</surname><given-names>A</given-names></name><name><surname>Hirao</surname><given-names>Y</given-names></name><name><surname>Fujimoto</surname><given-names>K</given-names></name></person-group><article-title>Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer</article-title><source>BMC Urol</source><year>2014</year><volume>14</volume><issue>1</issue><fpage>3</fpage><pub-id pub-id-type="pmid">24397735</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banu</surname><given-names>A</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Banu</surname><given-names>E</given-names></name><name><surname>Kamioneur</surname><given-names>D</given-names></name><name><surname>Housset</surname><given-names>M</given-names></name><name><surname>Thiounn</surname><given-names>N</given-names></name><name><surname>Scotte</surname><given-names>F</given-names></name><name><surname>Jenabian</surname><given-names>A</given-names></name><name><surname>Mejean</surname><given-names>A</given-names></name><name><surname>Andrieu</surname><given-names>JM</given-names></name></person-group><article-title>Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database</article-title><source>Int J Urol</source><year>2015</year><volume>22</volume><issue>4</issue><fpage>362</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">25728968</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakkar</surname><given-names>R</given-names></name><name><surname>Gershenson</surname><given-names>D</given-names></name><name><surname>Fox</surname><given-names>P</given-names></name><name><surname>Vu</surname><given-names>K</given-names></name><name><surname>Zenali</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>E</given-names></name></person-group><article-title>Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses</article-title><source>Int J Gynecol Pathol</source><year>2014</year><volume>33</volume><issue>3</issue><fpage>302</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">24681743</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falchook</surname><given-names>AD</given-names></name><name><surname>Martin</surname><given-names>NE</given-names></name><name><surname>Basak</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>AB</given-names></name><name><surname>Milowsky</surname><given-names>MI</given-names></name><name><surname>Chen</surname><given-names>RC</given-names></name></person-group><article-title>Stage at presentation and survival outcomes of patients with Gleason 8&#x02013;10 prostate cancer and low prostate-specific antigen</article-title><source>Urol Oncol</source><year>2016</year><volume>34</volume><issue>3</issue><fpage>119.e119</fpage><lpage>119.e126</lpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sfanos</surname><given-names>KS</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name></person-group><article-title>Prostate cancer and inflammation: the evidence</article-title><source>Histopathology</source><year>2011</year><volume>60</volume><issue>1</issue><fpage>199</fpage><lpage>215</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vignozzi</surname><given-names>L</given-names></name><name><surname>Maggi</surname><given-names>M</given-names></name></person-group><article-title>Prostate cancer: intriguing data on inflammation and prostate cancer</article-title><source>Nat Rev Urol</source><year>2014</year><volume>11</volume><issue>7</issue><fpage>369</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">24980193</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name></person-group><article-title>Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><issue>1</issue><fpage>443</fpage><pub-id pub-id-type="pmid">29669528</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolan</surname><given-names>RD</given-names></name><name><surname>Lim</surname><given-names>J</given-names></name><name><surname>Mcsorley</surname><given-names>ST</given-names></name><name><surname>Horgan</surname><given-names>PG</given-names></name><name><surname>Mcmillan</surname><given-names>DC</given-names></name></person-group><article-title>The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>16717</fpage><pub-id pub-id-type="pmid">29196718</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Mei</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Long</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name></person-group><article-title>Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil&#x02013;lymphocyte ratio and platelet-lymphocyte ratio</article-title><source>Head Neck</source><year>2016</year><volume>38</volume><issue>S1</issue><fpage>E1332</fpage><lpage>E1340</lpage><pub-id pub-id-type="pmid">26362911</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasui</surname><given-names>MHY</given-names></name><name><surname>Kawahara</surname><given-names>T</given-names></name><name><surname>Kumano</surname><given-names>Y</given-names></name><name><surname>Miyoshi</surname><given-names>Y</given-names></name><name><surname>Matsubara</surname><given-names>N</given-names></name><name><surname>Uemura</surname><given-names>H</given-names></name></person-group><article-title>Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate</article-title><source>Mol Clin Oncol</source><year>2018</year><volume>8</volume><issue>4</issue><fpage>592</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">29541468</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langsenlehner</surname><given-names>T</given-names></name><name><surname>Pichler</surname><given-names>M</given-names></name><name><surname>Thurner</surname><given-names>EM</given-names></name><name><surname>Krenn-Pilko</surname><given-names>S</given-names></name><name><surname>Stojakovic</surname><given-names>T</given-names></name><name><surname>Gerger</surname><given-names>A</given-names></name><name><surname>Langsenlehner</surname><given-names>U</given-names></name></person-group><article-title>Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy</article-title><source>Urol Oncol</source><year>2015</year><volume>33</volume><issue>5</issue><fpage>201.e9</fpage><lpage>201.e16</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigeta</surname><given-names>K</given-names></name><name><surname>Kosaka</surname><given-names>T</given-names></name><name><surname>Kitano</surname><given-names>S</given-names></name><name><surname>Yasumizu</surname><given-names>Y</given-names></name><name><surname>Miyazaki</surname><given-names>Y</given-names></name><name><surname>Mizuno</surname><given-names>R</given-names></name><name><surname>Shinojima</surname><given-names>T</given-names></name><name><surname>Kikuchi</surname><given-names>E</given-names></name><name><surname>Miyajima</surname><given-names>A</given-names></name><name><surname>Tanoguchi</surname><given-names>H</given-names></name></person-group><article-title>High absolute monocyte count predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy</article-title><source>Ann Surg Oncol</source><year>2016</year><volume>195</volume><issue>4</issue><fpage>e310</fpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linton</surname><given-names>A</given-names></name><name><surname>Pond</surname><given-names>G</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Vardy</surname><given-names>J</given-names></name><name><surname>Galsky</surname><given-names>M</given-names></name><name><surname>Sonpavde</surname><given-names>G</given-names></name></person-group><article-title>Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy</article-title><source>Clin Genitourin Cancer</source><year>2013</year><volume>11</volume><issue>4</issue><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">23816526</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>GM</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>XC</given-names></name><name><surname>Qin</surname><given-names>XJ</given-names></name><name><surname>Wan</surname><given-names>FN</given-names></name><name><surname>Dai</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>LJ</given-names></name><name><surname>Ye</surname><given-names>DW</given-names></name></person-group><article-title>Pretreatment neutrophil-to-lymphocyte ratio: a predictor of advanced prostate cancer and biochemical recurrence in patients receiving radical prostatectomy</article-title><source>Medicine</source><year>2015</year><volume>94</volume><issue>41</issue><fpage>e1473</fpage><pub-id pub-id-type="pmid">26469891</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Ju</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name></person-group><article-title>Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer</article-title><source>J Clin Lab Anal</source><year>2017</year><volume>32</volume><issue>3</issue><fpage>e22277</fpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>LWR</given-names></name><name><surname>Chi</surname><given-names>C</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Shangguan</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>B</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name></person-group><article-title>Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients</article-title><source>Prostate</source><year>2018</year><volume>78</volume><issue>4</issue><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">29285775</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Cockerill</surname><given-names>PA</given-names></name><name><surname>Viers</surname><given-names>BR</given-names></name><name><surname>Rangel</surname><given-names>LJ</given-names></name><name><surname>Carlson</surname><given-names>RE</given-names></name><name><surname>Karnes</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Mp6-05 the association of preoperative neutrophil to lymphocyte ratio with oncologic outcomes following radical prostatectomy for prostate cancer</article-title><source>J Urol</source><year>2015</year><volume>193</volume><fpage>e55</fpage><lpage>e56</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Qi</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name></person-group><article-title>Prognostic role of neutrophil-to-lymphocyte ratio in prostate cancer: a systematic review and meta-analysis</article-title><source>Medicine</source><year>2016</year><volume>95</volume><issue>3</issue><fpage>e2544</fpage><pub-id pub-id-type="pmid">26817900</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>XF</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name></person-group><article-title>Neutrophil-to-lymphocyte ratio predicts PSA response and prognosis in prostate cancer: a systematic review and meta-analysis</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><issue>7</issue><fpage>e0158770</fpage><pub-id pub-id-type="pmid">27368058</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xin</surname><given-names>P</given-names></name><name><surname>Bi</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>C</given-names></name></person-group><article-title>Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>41</issue><fpage>70874</fpage><lpage>70882</lpage><pub-id pub-id-type="pmid">29050328</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shamseer</surname><given-names>L</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name><name><surname>Ghersi</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Petticrew</surname><given-names>M</given-names></name><name><surname>Shekelle</surname><given-names>P</given-names></name><name><surname>Stewart</surname><given-names>LA</given-names></name></person-group><article-title>Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation</article-title><source>BMJ</source><year>2015</year><volume>349</volume><issue>1</issue><fpage>g7647</fpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>RD</given-names></name><name><surname>Moons</surname><given-names>KGM</given-names></name><name><surname>Snell</surname><given-names>KIE</given-names></name><name><surname>Ensor</surname><given-names>J</given-names></name><name><surname>Hooft</surname><given-names>L</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Hayden</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>GS</given-names></name><name><surname>Debray</surname><given-names>TPA</given-names></name></person-group><article-title>A guide to systematic review and meta-analysis of prognostic factor studies</article-title><source>BMJ</source><year>2019</year><volume>30</volume><issue>364</issue><fpage>k4597</fpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stang</surname><given-names>A</given-names></name></person-group><article-title>Critical evaluation of the Newcastle&#x02013;Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses</article-title><source>Eur J Epidemiol</source><year>2010</year><volume>25</volume><issue>9</issue><fpage>603</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">20652370</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JPT</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>327</volume><issue>7414</issue><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">12958120</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>MDSG</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Minder</surname><given-names>C</given-names></name></person-group><article-title>Bias in meta-analysis detected by a simple, graphical test</article-title><source>BMJ</source><year>1997</year><volume>315</volume><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">9310563</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duval</surname><given-names>S</given-names></name><name><surname>Tweedie</surname><given-names>R</given-names></name></person-group><article-title>Trim and fill: a simple funnel-plot&#x02013;based method of testing and adjusting for publication bias in meta-analysis</article-title><source>Biometrics</source><year>2000</year><volume>56</volume><issue>2</issue><fpage>455</fpage><pub-id pub-id-type="pmid">10877304</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conteduca</surname><given-names>VCO</given-names></name><name><surname>Galli</surname><given-names>L</given-names></name><name><surname>Maugeri</surname><given-names>A</given-names></name><name><surname>Scarpi</surname><given-names>E</given-names></name><name><surname>Maines</surname><given-names>F</given-names></name><name><surname>Chiuri</surname><given-names>VE</given-names></name><name><surname>Lolli</surname><given-names>C</given-names></name><name><surname>Kinspergher</surname><given-names>S</given-names></name><name><surname>Schepisi</surname><given-names>G</given-names></name><name><surname>Santoni</surname><given-names>M</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Fratino</surname><given-names>L</given-names></name><name><surname>Burgio</surname><given-names>SL</given-names></name><name><surname>Salvi</surname><given-names>S</given-names></name><name><surname>Menna</surname><given-names>C</given-names></name><name><surname>De Giorgi</surname><given-names>U</given-names></name></person-group><article-title>Association among metabolic syndrome, inflammation, and survival in prostate cancer</article-title><source>Urol Oncol</source><year>2018</year><volume>36</volume><issue>5</issue><fpage>240.e201</fpage><lpage>240.e211</lpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidal</surname><given-names>AC</given-names></name><name><surname>Howard</surname><given-names>LE</given-names></name><name><surname>Hoedt</surname><given-names>AD</given-names></name><name><surname>Cooperberg</surname><given-names>MR</given-names></name><name><surname>Kane</surname><given-names>CJ</given-names></name><name><surname>Aronson</surname><given-names>WJ</given-names></name><name><surname>Terris</surname><given-names>MK</given-names></name><name><surname>Amling</surname><given-names>CL</given-names></name><name><surname>Taioli</surname><given-names>E</given-names></name><name><surname>Fowke</surname><given-names>JH</given-names></name></person-group><article-title>Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database</article-title><source>Cancer Causes Control</source><year>2018</year><volume>29</volume><issue>6</issue><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">29663110</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>K</given-names></name><name><surname>Kawahara</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>D</given-names></name><name><surname>Jikuya</surname><given-names>R</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Tatenuma</surname><given-names>T</given-names></name><name><surname>Yokomizo</surname><given-names>Y</given-names></name><name><surname>Izumi</surname><given-names>K</given-names></name><name><surname>Teranishi</surname><given-names>JI</given-names></name><name><surname>Makiyama</surname><given-names>K</given-names></name></person-group><article-title>Neutrophil-to-lymphocyte ratio predicts prognosis in castration-resistant prostate cancer patients who received cabazitaxel chemotherapy</article-title><source>Biomed Res Int</source><year>2017</year><volume>2017</volume><fpage>7538647</fpage><pub-id pub-id-type="pmid">28948170</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehra</surname><given-names>NSA</given-names></name><name><surname>Lorente</surname><given-names>D</given-names></name><name><surname>Dolling</surname><given-names>D</given-names></name><name><surname>Sumanasuriya</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>B</given-names></name><name><surname>Dearnaley</surname><given-names>D</given-names></name><name><surname>Parker</surname><given-names>C</given-names></name><name><surname>de Bono</surname><given-names>J</given-names></name></person-group><article-title>Neutrophil to lymphocyte ratio in castration-resistant prostate cancer patients treated with daily oral corticosteroids</article-title><source>Clin Genitourin Cancer</source><year>2017</year><volume>15</volume><issue>6</issue><fpage>678</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">28606735</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boegemann</surname><given-names>M</given-names></name><name><surname>Schlack</surname><given-names>K</given-names></name><name><surname>Thomes</surname><given-names>S</given-names></name><name><surname>Steinestel</surname><given-names>J</given-names></name><name><surname>Rahbar</surname><given-names>K</given-names></name><name><surname>Semjonow</surname><given-names>A</given-names></name><name><surname>Schrader</surname><given-names>AJ</given-names></name><name><surname>Aringer</surname><given-names>M</given-names></name><name><surname>Krabbe</surname><given-names>LM</given-names></name></person-group><article-title>The role of the neutrophil to lymphocyte ratio for survival outcomes in patients with metastatic castration-resistant prostate cancer treated with abiraterone</article-title><source>Int J Mol Sci</source><year>2017</year><volume>18</volume><issue>2</issue><fpage>E380</fpage><pub-id pub-id-type="pmid">28208664</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>XQ</given-names></name><name><surname>He</surname><given-names>DL</given-names></name><name><surname>Tian</surname><given-names>G</given-names></name><name><surname>Lv</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>YM</given-names></name><name><surname>Wu</surname><given-names>DP</given-names></name><name><surname>Fan</surname><given-names>JH</given-names></name><name><surname>Wu</surname><given-names>KJ</given-names></name></person-group><article-title>Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China</article-title><source>Int Urol Nephrol</source><year>2017</year><volume>49</volume><issue>4</issue><fpage>629</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">28161841</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buttigliero</surname><given-names>CPC</given-names></name><name><surname>Tucci</surname><given-names>M</given-names></name><name><surname>Vignani</surname><given-names>F</given-names></name><name><surname>Bertaglia</surname><given-names>V</given-names></name><name><surname>Iaconis</surname><given-names>D</given-names></name><name><surname>Guglielmini</surname><given-names>P</given-names></name><name><surname>Numico</surname><given-names>G</given-names></name><name><surname>Scagliotti</surname><given-names>GV</given-names></name><name><surname>Di Maio</surname><given-names>M</given-names></name></person-group><article-title>Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel</article-title><source>Acta Oncol</source><year>2017</year><volume>56</volume><issue>4</issue><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">28068151</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>WS</given-names></name><name><surname>Cho</surname><given-names>KS</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Yoon</surname><given-names>CY</given-names></name><name><surname>Kang</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Ham</surname><given-names>WS</given-names></name><name><surname>Rha</surname><given-names>KH</given-names></name><name><surname>Hong</surname><given-names>SJ</given-names></name><name><surname>Choi</surname><given-names>YD</given-names></name></person-group><article-title>Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer</article-title><source>Prostate Cancer Prostatic Dis</source><year>2016</year><volume>19</volume><issue>3</issue><fpage>298</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">27349499</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lolli</surname><given-names>CCO</given-names></name><name><surname>Scarpi</surname><given-names>E</given-names></name><name><surname>Aieta</surname><given-names>M</given-names></name><name><surname>Conteduca</surname><given-names>V</given-names></name><name><surname>Maines</surname><given-names>F</given-names></name><name><surname>Bianchi</surname><given-names>E</given-names></name><name><surname>Massari</surname><given-names>F</given-names></name><name><surname>Veccia</surname><given-names>A</given-names></name><name><surname>Chiuri</surname><given-names>VE</given-names></name><name><surname>Facchini</surname><given-names>G</given-names></name><name><surname>De Giorgi</surname><given-names>U</given-names></name></person-group><article-title>Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone</article-title><source>Front Pharmacol</source><year>2015</year><volume>7</volume><fpage>376</fpage></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Jeong</surname><given-names>SJ</given-names></name><name><surname>Hong</surname><given-names>SK</given-names></name><name><surname>Byun</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Oh</surname><given-names>JJ</given-names></name></person-group><article-title>High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy</article-title><source>World J Urol</source><year>2016</year><volume>34</volume><issue>6</issue><fpage>821</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">26449784</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>X</given-names></name><name><surname>Sha</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Dong</surname><given-names>B</given-names></name></person-group><article-title>Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy</article-title><source>BMC Cancer</source><year>2016</year><volume>16</volume><issue>1</issue><fpage>329</fpage><pub-id pub-id-type="pmid">27222030</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langsenlehner</surname><given-names>T</given-names></name><name><surname>Thurner</surname><given-names>EM</given-names></name><name><surname>Krenn-Pilko</surname><given-names>S</given-names></name><name><surname>Langsenlehner</surname><given-names>U</given-names></name><name><surname>Stojakovic</surname><given-names>T</given-names></name><name><surname>Gerger</surname><given-names>A</given-names></name><name><surname>Pichler</surname><given-names>M</given-names></name></person-group><article-title>Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients</article-title><source>World J Urol</source><year>2015</year><volume>33</volume><issue>11</issue><fpage>1661</fpage><lpage>1667</lpage><pub-id pub-id-type="pmid">25617235</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahig</surname><given-names>H</given-names></name><name><surname>Taussky</surname><given-names>D</given-names></name><name><surname>Delouya</surname><given-names>G</given-names></name><name><surname>Nadiri</surname><given-names>A</given-names></name><name><surname>Gagnon-Jacques</surname><given-names>A</given-names></name><name><surname>Bodson-Clermont</surname><given-names>P</given-names></name><name><surname>Soulieres</surname><given-names>D</given-names></name></person-group><article-title>Neutrophil count is associated with survival in localized prostate cancer</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><issue>1</issue><fpage>594</fpage><pub-id pub-id-type="pmid">26292807</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorente</surname><given-names>D</given-names></name><name><surname>Mateo</surname><given-names>J</given-names></name><name><surname>Templeton</surname><given-names>AJ</given-names></name><name><surname>Zafeiriou</surname><given-names>Z</given-names></name><name><surname>Bianchini</surname><given-names>D</given-names></name><name><surname>Ferraldeschi</surname><given-names>R</given-names></name><name><surname>Bahl</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Sartor</surname><given-names>O</given-names></name></person-group><article-title>Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use</article-title><source>Ann Oncol</source><year>2015</year><volume>26</volume><issue>4</issue><fpage>750</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">25538172</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>A</given-names></name><name><surname>Sejima</surname><given-names>T</given-names></name><name><surname>Iwamoto</surname><given-names>H</given-names></name><name><surname>Masago</surname><given-names>T</given-names></name><name><surname>Morizane</surname><given-names>S</given-names></name><name><surname>Honda</surname><given-names>M</given-names></name><name><surname>Takenaka</surname><given-names>A</given-names></name></person-group><article-title>High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy</article-title><source>Int J Urol</source><year>2015</year><volume>22</volume><issue>9</issue><fpage>827</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">26087772</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name></person-group><article-title>Platelet to lymphocyte ratio plays an important role in prostate cancer&#x02019;s diagnosis and prognosis</article-title><source>Int J Clin Exp Med</source><year>2015</year><volume>8</volume><issue>7</issue><fpage>11746</fpage><lpage>11751</lpage><pub-id pub-id-type="pmid">26380014</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonpavde</surname><given-names>G</given-names></name><name><surname>Pond</surname><given-names>GR</given-names></name><name><surname>Armstrong</surname><given-names>AJ</given-names></name><name><surname>Clarke</surname><given-names>SJ</given-names></name><name><surname>Vardy</surname><given-names>JL</given-names></name><name><surname>Templeton</surname><given-names>AJ</given-names></name><name><surname>Wang</surname><given-names>SL</given-names></name><name><surname>Paolini</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>Chow-Maneval</surname><given-names>E</given-names></name></person-group><article-title>Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer</article-title><source>Clin Genitourin Cancer</source><year>2014</year><volume>12</volume><issue>5</issue><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">24806399</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuhn</surname><given-names>P</given-names></name><name><surname>Vaghasia</surname><given-names>AM</given-names></name><name><surname>Goyal</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>XC</given-names></name><name><surname>Carducci</surname><given-names>MA</given-names></name><name><surname>Eisenberger</surname><given-names>MA</given-names></name><name><surname>Antonarakis</surname><given-names>ES</given-names></name></person-group><article-title>Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel</article-title><source>BJU Int</source><year>2014</year><volume>114</volume><issue>6b</issue><fpage>E11</fpage><lpage>E17</lpage><pub-id pub-id-type="pmid">24529213</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafique</surname><given-names>K</given-names></name><name><surname>Proctor</surname><given-names>MJ</given-names></name><name><surname>Mcmillan</surname><given-names>DC</given-names></name><name><surname>Qureshi</surname><given-names>K</given-names></name><name><surname>Leung</surname><given-names>H</given-names></name><name><surname>Morrison</surname><given-names>DS</given-names></name></person-group><article-title>Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study</article-title><source>Prostate Cancer Prostatic Dis</source><year>2012</year><volume>15</volume><issue>2</issue><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">22343838</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>S</given-names></name><name><surname>Tobiume</surname><given-names>M</given-names></name><name><surname>Zennami</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Nishikawa</surname><given-names>G</given-names></name><name><surname>Yoshizawa</surname><given-names>T</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Nakaoka</surname><given-names>A</given-names></name></person-group><article-title>Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer</article-title><source>Oncol Rep</source><year>2011</year><volume>25</volume><issue>4</issue><fpage>937</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">21249322</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YQ</given-names></name><name><surname>Zhu</surname><given-names>YJ</given-names></name><name><surname>Pan</surname><given-names>JH</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Shao</surname><given-names>XG</given-names></name><name><surname>Sha</surname><given-names>JJ</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>YR</given-names></name><name><surname>Dong</surname><given-names>BJ</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name></person-group><article-title>Peripheral monocyte count: an independent diagnostic and prognostic biomarker for prostate cancer&#x02014;a large Chinese cohort study</article-title><source>Asian J Androl</source><year>2017</year><volume>19</volume><issue>5</issue><fpage>579</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">27569002</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Templeton</surname><given-names>AJ</given-names></name><name><surname>Pezaro</surname><given-names>C</given-names></name><name><surname>Omlin</surname><given-names>A</given-names></name><name><surname>McNamara</surname><given-names>MG</given-names></name><name><surname>Leibowitz-Amit</surname><given-names>R</given-names></name><name><surname>Vera-Badillo</surname><given-names>FE</given-names></name><name><surname>Attard</surname><given-names>G</given-names></name><name><surname>de Bono</surname><given-names>JS</given-names></name><name><surname>Tannock</surname><given-names>IF</given-names></name><name><surname>Amir</surname><given-names>E</given-names></name></person-group><article-title>Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio</article-title><source>Cancer</source><year>2014</year><volume>120</volume><issue>21</issue><fpage>3346</fpage><lpage>3352</lpage><pub-id pub-id-type="pmid">24995769</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>AC</given-names></name><name><surname>Vira</surname><given-names>MA</given-names></name><name><surname>Vidal</surname><given-names>AC</given-names></name><name><surname>Gan</surname><given-names>W</given-names></name><name><surname>Freedland</surname><given-names>SJ</given-names></name><name><surname>Taioli</surname><given-names>E</given-names></name></person-group><article-title>Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease&#x02014;the 2001&#x02013;2008 National Health and Nutrition Examination Survey</article-title><source>Prostate</source><year>2014</year><volume>74</volume><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">24435840</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poyet</surname><given-names>C</given-names></name><name><surname>Adank</surname><given-names>J-P</given-names></name><name><surname>Keller</surname><given-names>E</given-names></name><name><surname>Mortezavi</surname><given-names>A</given-names></name><name><surname>Rabgang</surname><given-names>T</given-names></name><name><surname>Pfister</surname><given-names>B</given-names></name><etal/></person-group><article-title>Mp66-05 pretreatment systemic inflammatory response parameters do not predict the outcome in men with prostate cancer undergoing radical prostatectomy</article-title><source>J Urol</source><year>2015</year><volume>193</volume><fpage>e817</fpage></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Soest</surname><given-names>RJ</given-names></name><name><surname>Templeton</surname><given-names>AJ</given-names></name><name><surname>Vera-Badillo</surname><given-names>FE</given-names></name><name><surname>Mercier</surname><given-names>F</given-names></name><name><surname>Sonpavde</surname><given-names>G</given-names></name><name><surname>Amir</surname><given-names>E</given-names></name><name><surname>Tombal</surname><given-names>B</given-names></name><name><surname>Rosenthal</surname><given-names>M</given-names></name><name><surname>Eisenberger</surname><given-names>MA</given-names></name><name><surname>Tannock</surname><given-names>IF</given-names></name><name><surname>de Wit</surname><given-names>R</given-names></name></person-group><article-title>Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials</article-title><source>Ann Oncol</source><year>2015</year><volume>26</volume><issue>4</issue><fpage>743</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">25515657</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minardi</surname><given-names>D</given-names></name><name><surname>Scartozzi</surname><given-names>M</given-names></name><name><surname>Montesi</surname><given-names>L</given-names></name><name><surname>Santoni</surname><given-names>M</given-names></name><name><surname>Burattini</surname><given-names>L</given-names></name><name><surname>Bianconi</surname><given-names>M</given-names></name><name><surname>Lacetera</surname><given-names>V</given-names></name><name><surname>Milanese</surname><given-names>G</given-names></name><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Muzzonigro</surname><given-names>G</given-names></name></person-group><article-title>Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer</article-title><source>Springerplus</source><year>2015</year><volume>4</volume><fpage>255</fpage><pub-id pub-id-type="pmid">26085975</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>YS</given-names></name><name><surname>Han</surname><given-names>CS</given-names></name><name><surname>Yu</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Modi</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Ha</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>WJ</given-names></name><name><surname>Kim</surname><given-names>IY</given-names></name></person-group><article-title>Neutrophil and lymphocyte counts as clinical markers for stratifying low-risk prostate cancer</article-title><source>Clin Genitourin Cancer</source><year>2016</year><volume>14</volume><issue>1</issue><fpage>e1</fpage><lpage>e8</lpage><pub-id pub-id-type="pmid">26341038</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000fc;mb&#x000fc;l</surname><given-names>AT</given-names></name><name><surname>Sezer</surname><given-names>A</given-names></name><name><surname>Abal&#x00131;</surname><given-names>H</given-names></name><name><surname>K&#x000f6;se</surname><given-names>F</given-names></name><name><surname>G&#x000fc;ltepe</surname><given-names>I</given-names></name><name><surname>Mertsoylu</surname><given-names>H</given-names></name><name><surname>Muallao&#x0011f;lu</surname><given-names>S</given-names></name><name><surname>&#x000d6;zy&#x00131;lkan</surname><given-names>&#x000d6;</given-names></name></person-group><article-title>Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel</article-title><source>Int Urol Nephrol</source><year>2014</year><volume>46</volume><issue>8</issue><fpage>1531</fpage><lpage>1535</lpage><pub-id pub-id-type="pmid">24526335</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagami</surname><given-names>Y</given-names></name><name><surname>Nakashima</surname><given-names>J</given-names></name><name><surname>Ohno</surname><given-names>Y</given-names></name><name><surname>Makoto</surname><given-names>O</given-names></name><name><surname>Tachibana</surname><given-names>M</given-names></name></person-group><article-title>Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel risk stratification model in castration-resistant prostate cancer patients treated with docetaxel chemotherapy</article-title><source>J Urol</source><year>2015</year><volume>193</volume><issue>4</issue><fpage>e1084</fpage></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keizman</surname><given-names>D</given-names></name><name><surname>Gottfried</surname><given-names>M</given-names></name><name><surname>Ish-Shalom</surname><given-names>M</given-names></name><name><surname>Maimon</surname><given-names>N</given-names></name><name><surname>Peer</surname><given-names>A</given-names></name><name><surname>Neumann</surname><given-names>A</given-names></name><name><surname>Rosenbaum</surname><given-names>E</given-names></name><name><surname>Kovel</surname><given-names>S</given-names></name><name><surname>Pili</surname><given-names>R</given-names></name><name><surname>Sinibaldi</surname><given-names>V</given-names></name><name><surname>Carducci</surname><given-names>MA</given-names></name><name><surname>Hammers</surname><given-names>H</given-names></name><name><surname>Eisenberger</surname><given-names>MA</given-names></name><name><surname>Sella</surname><given-names>A</given-names></name></person-group><article-title>Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram</article-title><source>Oncologist</source><year>2012</year><volume>17</volume><issue>12</issue><fpage>1508</fpage><lpage>1514</lpage><pub-id pub-id-type="pmid">22971522</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donati</surname><given-names>K</given-names></name><name><surname>S&#x000e9;pult</surname><given-names>C</given-names></name><name><surname>Rocks</surname><given-names>N</given-names></name><name><surname>Blacher</surname><given-names>S</given-names></name><name><surname>G&#x000e9;rard</surname><given-names>C</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name><name><surname>Cataldo</surname><given-names>D</given-names></name></person-group><article-title>Neutrophil-derived interleukin 16 in premetastatic lungs promotes breast tumor cell seeding</article-title><source>Cancer Growth Metastasis</source><year>2017</year><volume>10</volume><fpage>1179064417738513</fpage><pub-id pub-id-type="pmid">29123422</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spicer</surname><given-names>JD</given-names></name><name><surname>Mcdonald</surname><given-names>B</given-names></name><name><surname>Coolslartigue</surname><given-names>JJ</given-names></name><name><surname>Chow</surname><given-names>SC</given-names></name><name><surname>Giannias</surname><given-names>B</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name><name><surname>Ferri</surname><given-names>LE</given-names></name></person-group><article-title>Neutrophils promote liver metastasis via Mac-1-mediated interactions with circulating tumor cells</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><issue>16</issue><fpage>3919</fpage><lpage>3927</lpage><pub-id pub-id-type="pmid">22751466</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><article-title>Melatonin represses oral squamous cell carcinoma metastasis by inhibiting tumor-associated neutrophils</article-title><source>Am J Transl Res</source><year>2017</year><volume>9</volume><issue>12</issue><fpage>5361</fpage><lpage>5374</lpage><pub-id pub-id-type="pmid">29312489</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wculek</surname><given-names>SK</given-names></name><name><surname>Malanchi</surname><given-names>I</given-names></name></person-group><article-title>Neutrophils support lung colonization of metastasis-initiating breast cancer cells</article-title><source>Nature</source><year>2015</year><volume>528</volume><issue>7582</issue><fpage>413</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">26649828</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffelt</surname><given-names>SB</given-names></name><name><surname>Kersten</surname><given-names>K</given-names></name><name><surname>Doornebal</surname><given-names>CW</given-names></name><name><surname>Weiden</surname><given-names>J</given-names></name><name><surname>Vrijland</surname><given-names>K</given-names></name><name><surname>Hau</surname><given-names>CS</given-names></name><name><surname>Njm</surname><given-names>V</given-names></name><name><surname>Ciampricotti</surname><given-names>M</given-names></name><name><surname>Ljac</surname><given-names>H</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name></person-group><article-title>IL-17-producing &#x003b3;&#x003b4; T cells and neutrophils conspire to promote breast cancer metastasis</article-title><source>Nature</source><year>2015</year><volume>522</volume><issue>7556</issue><fpage>345</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">25822788</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><article-title>Platelet-derived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells</article-title><source>J Cell Biochem</source><year>2013</year><volume>114</volume><issue>7</issue><fpage>1510</fpage><lpage>1518</lpage><pub-id pub-id-type="pmid">23297038</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavassani</surname><given-names>KAMR</given-names></name><name><surname>Habiel</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>JF</given-names></name><name><surname>Montes</surname><given-names>A</given-names></name><name><surname>Tripathi</surname><given-names>M</given-names></name><name><surname>Martins</surname><given-names>GA</given-names></name><name><surname>Crother</surname><given-names>TR</given-names></name><name><surname>You</surname><given-names>S</given-names></name><name><surname>Hogaboam</surname><given-names>CM</given-names></name><name><surname>Bhowmick</surname><given-names>N</given-names></name><name><surname>Posadas</surname><given-names>EM</given-names></name></person-group><article-title>Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells</article-title><source>Cancer Med</source><year>2018</year><volume>7</volume><issue>9</issue><fpage>4639</fpage><lpage>4649</lpage><pub-id pub-id-type="pmid">30094958</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsagozis</surname><given-names>P</given-names></name><name><surname>Augsten</surname><given-names>M</given-names></name><name><surname>Pisa</surname><given-names>P</given-names></name></person-group><article-title>All trans-retinoic acid abrogates the pro-tumorigenic phenotype of prostate cancer tumor-associated macrophages</article-title><source>Int Immunopharmacol</source><year>2014</year><volume>23</volume><issue>1</issue><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">25130608</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>YH</given-names></name><name><surname>Sun</surname><given-names>HF</given-names></name><name><surname>Zhang</surname><given-names>YB</given-names></name><name><surname>Liao</surname><given-names>ZJ</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>JR</given-names></name><name><surname>Nan</surname><given-names>KJ</given-names></name><name><surname>Wang</surname><given-names>SH</given-names></name></person-group><article-title>The clinical use of the platelet/lymphocyte ratio and lymphocyte/monocyte ratio as prognostic predictors in colorectal cancer: a meta-analysis</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>12</issue><fpage>20011</fpage><lpage>20024</lpage><pub-id pub-id-type="pmid">28212553</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name></person-group><article-title>Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis</article-title><source>Leuk Lymphoma</source><year>2015</year><volume>56</volume><issue>9</issue><fpage>2563</fpage><lpage>2568</lpage><pub-id pub-id-type="pmid">25686648</pub-id></element-citation></ref></ref-list></back></article>